Report and Recommendations of Stage 2 Feasibility Research into the Controlled Availability of Opioids by Bammer, Gabriele
i  REPORT AND RECOMMENDATIONS
of
Stage 2
Feasibility Research into the Controlled
Availability of Opioids
Gabriele Bammer
Fellow
National Centre for Epidemiology and Population Health
The Australian National University
with a Foreword by
Professor RM Douglas
Director
National Centre for Epidemiology and Population Health
The Australian National University
and
Dr Adam Graycar
Director
Australian Institute of Criminology
June 1995
N A T I O N A L  C E N T R E  F O R
E P I D E M I O L O G Y  A N D
P O P U L A T I O N  H E A L T H
A U S T R A L I A N
I N S T I T U T E  O F
Table of contents
ii
C R I M I N O L O G Y
Table of contents
iii
Report and Recommendations of Stage 2 Feasibility Research into the
Controlled Availability of Opioids
Gabriele Bammer
Feasibility Research into the Controlled Availability of Opioids Stage 2
National Centre for Epidemiology and Population Health, The Australian
National University &
The Australian Institute of Criminology
ISBN 07315 2159 5
ISSN 1039–088X
© National Centre for Epidemiology and Population Health 1995
This publication is copyright. Other than for the purposes of and subject to
the conditions prescribed under the Copyright Act, no part of it may in any
form or by any means be reproduced, stored in a retrieval system or
transmitted without prior written permission. Enquiries should be addressed
to the National Centre for Epidemiology and Population Health.
Published by the National Centre for Epidemiology and Population Health
The Australian National University
Canberra ACT 0200
June 1995
Cover designed by Samantha Seery, ANU Graphic Design, The Australian
National University,
Canberra, ACT 0200.
Publications Officer: Jennifer Braid, NCEPH
Table of contents
iv
Foreword
The feasibility research described here resulted from a partnership
between our two institutions. It has been carried out under the
direction of Dr Gabriele Bammer. We have co-chaired the meetings of
the Advisory Committee, which have had Australia-wide representation
from policy-makers, police, judiciary, treatment-service providers,
academics and advocates for illicit drug users. It was agreed at the
outset that the Advisory Committee would not take responsibility for
the report and its recommendations. That responsibility rests with
us and Dr Bammer.
We now have pleasure in presenting the findings of Stage 2 of
the feasibility research and believe that it is now both feasible
and desirable to proceed to a third stage of two pilot studies to be
carried out in the ACT.  These studies will determine whether a
fourth stage definitive study in three Australian cities is
practicable and/or desirable.
We thank the many people who have collaborated in the studies
that made up the Stage 2 research; the 19 members of our Advisory
Committee; and innumerable others who contributed in smaller, but no
less important ways. Over the past four years, the research has
painstakingly considered the risks involved in prescribing
diacetylmorphine (heroin) to dependent users. We have concluded that
the risks could be minimised and that they are outweighed by the
potential benefits. The careful design of the clinical service
incorporates numerous crucial safeguards.
We have thought carefully about the best form of evaluation for
a trial and have concluded that the core should be a randomised
controlled trial that will examine the following clinical question:
If maintenance treatment for opioid dependence is expanded
so that both injectable diacetylmorphine (heroin) and oral
methadone are available, is this more effective than
current maintenance treatment which involves the provision
of oral methadone only?
In addition to the clinical issues, the research must have a
strong criminological component which examines the social impact of
expanded maintenance treatment, particularly the effects on crime.
Well-run and rigorously evaluated pilots and a definitive trial
will require extensive financial support. The studies carried out
over the past four years have cost nearly $1 million, with a major
contribution from the ANU’s Strategic Development Fund. We believe
this is an issue of national significance and that, while the
processes should now be pretested in the ACT, national funds will be
needed to carry the issue forward.
There is now a need for wide community discussion of the issues
raised by our recommendations. Our research reveals that both the
ACT community and the broader Australian community are convinced
that new approaches to the “heroin problem” are required. The steps
proposed here are designed to move cautiously and with scientific
rigour in an evaluation of alternatives. This is an area in which
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there is remarkably little hard evidence. Preliminary experience
from trials of diacetylmorphine prescribing in Switzerland is,
however, reassuring. We believe the proposals described here are
practicable, explore new territory and would contribute
substantially to sound policy and treatment development for
Australia.
RM Douglas
Director
National Centre for Epidemiology
and Population Health
The Australian National University
Adam Graycar
Director
Australian Institute of Criminology
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Executive Summary
This report is the culmination of four years of research into the
question: Should a carefully controlled and rigorously evaluated
trial be conducted to determine whether or not the prescription of
pharmaceutical heroin (diacetylmorphine) is a useful addition to
current maintenance treatment for dependent heroin users?
It recommends that two carefully controlled pilot studies
should be conducted in Canberra. However, the addition of
diacetylmorphine to maintenance treatment must not be linked with
permissive attitudes to illicit drug use and must be coupled with
continuing law enforcement and prevention activity against illicit
drug use.
There is a sixteen-year history in Australia of government
consideration of the issue of diacetylmorphine maintenance
treatment. In 1991 the ACT Legislative Assembly Select Committee on
HIV, Illegal Drugs and Prostitution asked the National Centre for
Epidemiology and Population Health at The Australian National
University to investigate the issue and, in collaboration with the
Australian Institute of Criminology, research into in-principle and
logistic feasibility was undertaken.
It was found that a trial would not place Australia in breach
of international treaties. ACT and other laws will have to be
changed for a trial to proceed and the Commonwealth must grant
licences and permissions.
There is considerable community support, both in the ACT and
nationally, for new approaches to the problem of heroin dependence
and, although there is a degree of uncertainty about an ACT-based
trial, there is more support than opposition to it, particularly in
Canberra. There should now be a three-month consultation period to
allow the feasibility study findings to be scrutinised and discussed
as widely as possible.
Of all the interest groups, the police have the most concerns
about a trial, and their concerns were carefully considered in the
feasibility investigations. Limiting participant eligibility to
restricted numbers of users registered with the ACT methadone
program and resident in the ACT since 1993 will minimise the risk
that dependent users might move to the ACT from elsewhere in
Australia. There are also safeguards to prevent participants from
driving while affected by diacetylmorphine and strict security
provisions, including administration of diacetylmorphine only at the
clinic under close supervision.
Other potential risks were carefully scrutinised and ways to
minimise them determined. By minimising the risks, it becomes
feasible to evaluate the potential benefits of expanding maintenance
treatment to include diacetylmorphine. The potential benefits
include decreased crime and improved health and social integration.
The pilots and trial will be of national significance. It is
estimated that establishing and conducting an initial six-month
pilot with 40 participants will cost around $800,000 and a second
six-month pilot with 250 participants will cost $1.5 million. These
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pilot studies will determine whether or not a multi-centre two-year
trial involving three Australian cities should be undertaken.
Evidence is accumulating that treatment of illicit drug users is
more cost-effective than leaving them in the community untreated or
sending them to jail. Initial estimates suggest that expanded
maintenance treatment which includes diacetylmorphine would cost the
community less than one-tenth of the cost of an untreated illicit
heroin user and would be substantially cheaper than some current
treatments. The pilots and trial provide the possibility of
significantly strengthening treatment options.
Part 3: Results of the feasibility
research
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Recommendations
Recommendation 1. That two carefully controlled pilot studies are
conducted in Canberra to assess the addition of injectable
diacetylmorphine to maintenance treatment for registered dependent
users. If these produce positive outcomes, that a full-scale trial
of expanded maintenance treatment which includes injectable
diacetylmorphine is conducted in at least three Australian cities.
Recommendation 2. That the exploration of expanding maintenance
treatment to include injectable diacetylmorphine is coupled with
continuing law enforcement and prevention activity to control
illicit drug use. The addition of diacetylmorphine to maintenance
treatment should not be linked with permissive attitudes to illicit
drug use.
Recommendation 3. That the first pilot study is conducted with 40
established ACT resident volunteers who have either dropped out of
ACT methadone treatment or who are current ACT methadone clients who
would prefer the expanded treatment option. That, over a six-month
period, the study examines the following questions:
• can the addition of injectable diacetylmorphine to maintenance
treatment for dependent heroin users be undertaken successfully on
a small scale in the Australian context?
• can dependent heroin users be stabilised on injectable
diacetylmorphine or injectable diacetylmorphine plus oral
methadone and what are the optimum dosage ranges?
• can injectable diacetylmorphine maintenance treatment be
successfully integrated with oral methadone maintenance treatment
to provide flexibility in treatment?
• does the expansion of maintenance treatment to include injectable
diacetylmorphine improve the health and social functioning and
reduce the criminal behaviour of participants?
• is it possible to develop a package of indicators to measure the
social impact of adding injectable diacetylmorphine to maintenance
treatment?
Recommendation 4: Pilot study 1 will be deemed a success if the
following criteria are met:
• that a stable maintenance dose of injectable diacetylmorphine or
injectable diacetylmorphine plus oral methadone is found for more
than half of the participants;
• that injectable diacetylmorphine maintenance treatment can be
successfully integrated with oral methadone maintenance treatment;
• that there are indications of improvements in at least half of the
outcome measures pertaining to health, criminal behaviour and
social functioning;
Feasibility research results
12
• that workable measures of social impact are determined.
Recommendation 5. If pilot study 1 is a success, that a second pilot
study is conducted with 250 dependent heroin users drawn from
volunteers who have been resident in the ACT since 1993, and who
have dropped out of ACT methadone treatment, or who are current ACT
methadone clients who would prefer the expanded treatment option.
That, over a six month period, this pilot address the following
questions:
• does the addition to maintenance treatment of injectable
diacetylmorphine attract back and retain in treatment dependent
heroin users who have dropped out of methadone treatment?
• does the expansion of maintenance treatment to include
diacetylmorphine improve retention in treatment for those drawn
from current methadone clients?
• is it possible to conduct a successful randomised controlled trial
with dependent heroin users when the highly desirable ‘choice’
option, which provides injectable diacetylmorphine, is available
to only half of the participants?
• does the addition of injectable diacetylmorphine to maintenance
treatment produce better outcomes in terms of health, criminal
behaviour and social functioning.
• can dependent heroin users be stabilised on injectable
diacetylmorphine or injectable diacetylmorphine plus oral
methadone, on a large scale?
• can injectable diacetylmorphine maintenance treatment be
integrated successfully with oral methadone maintenance treatment
to provide flexibility in treatment, on a large scale?
• are the individual measures of outcomes ‘workable’; in other words
can the questionnaires be administered without undue respondent
burden and can the results be analysed in a timely fashion? If new
measures are used, are they valid and reliable?
• is the package of indicators developed to measure the social
effects of a trial workable? Have there been any major negative
social effects?
Recommendation 6: Pilot study 2 will be deemed a success if the
following criteria are met:
• that there is an indication that dependent heroin users, who have
dropped out of methadone treatment, are attracted back to
treatment and that the retention rate for both this group and for
those recruited from current methadone clients is better than for
participants who receive oral methadone only.
• that the process of randomising participants into two groups, only
one of which receives the choice of injectable diacetylmorphine
prescription, is shown to be feasible for evaluating the multi-
centre two-year trial.
• that at the end of six months, there are indications of
improvements in at least half of the outcome measures pertaining
to health, criminal behaviour and social functioning.
Feasibility research results
13
• that a stable maintenance dose of injectable diacetylmorphine or
injectable diacetylmorphine plus oral methadone can be found for
more than half of the participants in the ‘choice’ group.
• that injectable diacetylmorphine maintenance treatment can be
integrated successfully with oral methadone maintenance treatment.
• that individual measures of outcomes are determined to be
workable.
• that the package of indicators developed to measure the social
impact of diacetylmorphine prescribing is workable and there have
been no major negative effects.
Recommendation 7: If the pilot studies are shown to be successful,
that a two-year trial with 1000 participants is conducted in three
Australian cities. That it target three groups of dependent heroin
users—those who have never been in treatment, those who have dropped
out of treatment, and current methadone clients who would prefer the
expanded treatment option. That it address the following questions:
• can the availability of injectable diacetylmorphine as part of
maintenance treatment attract into and retain in treatment, people
who have not previously been in treatment?
• does the addition to maintenance treatment of injectable
diacetylmorphine attract back and retain in treatment dependent
heroin users who have dropped out of methadone treatment?
• does the expansion of maintenance treatment, to include
diacetylmorphine, improve retention in treatment for those drawn
from current methadone clients?
• for each of the three target groups, does providing a choice of
treatment which includes the option of injectable diacetylmorphine
improve outcomes over the option of oral methadone only?
Participants in the ‘choice’ and ‘control’ groups will be compared
on the following measures: health, criminal behaviours and social
functioning. If the outcomes are positive in the first year, all
participants will be allocated to the ‘choice’ group for a second
year, to test if the positive outcomes can be sustained.
• what is the social impact of expanding maintenance treatment to
include diacetylmorphine prescription?
• is adding diacetylmorphine to maintenance treatment cost-
effective?
Recommendation 8. That the service provision for the pilot studies
and the ACT component of the trial is provided by the Alcohol and
Drug Service of ACT Health. That the independent evaluation is
conducted jointly by the National Centre for Epidemiology and
Population Health at The Australian National University and the
Australian Institute of Criminology. That a committee is established
to oversee the running of the pilot studies and the ACT component of
the trial. Its membership should include representatives from the
clinical staff, participants and researchers; the police and
judiciary; the medical profession and non-government treatment
services; ACT Health and the ACT Attorney-General’s Department;
relevant Commonwealth departments; and an ethicist. That this
committee will recommend to the ACT Legislative Assembly whether or
Feasibility research results
14
not there should be progression from pilot 1 to pilot 2 and from
pilot 2 to a trial or if the prescription of injectable
diacetylmorphine should be stopped at any time.
Recommendation 9: That, noting the national significance of the ACT-
based pilot studies, there is extensive financial support from
outside the ACT to fund the pilot studies.
Recommendation 10: That the ACT government institutes a three-month
consultation period in which the results of the feasibility research
are widely disseminated and discussed. That a committee is
established to receive and consider the feedback from groups and
individuals. That the committee includes representation from the ACT
Health Alcohol and Drug Service; the police and judiciary; the ACT
Attorney-General’s Department; relevant Commonwealth departments;
illicit heroin users; the medical profession and non-government
treatment services; an ethicist; and the Director of the Feasibility
Research. That the committee reports to the ACT Minister for Health
on the results of the consultation no later than 31 October 1995.
Recommendation 11: That the ACT Health Alcohol and Drug Service is
proactive in disseminating information about eligibility criteria to
drug treatment services and user advocacy groups around Australia.
Recommendation 12: That, to establish the first pilot study, the ACT
Legislative Assembly either amend existing legislation or introduce
special legislation to make diacetylmorphine available for carefully
controlled and limited medical prescription. That the ACT government
liaise with the Commonwealth and other States about the passage of
relevant legislation and the provision of the necessary licences and
permissions. That a service manager and a senior specialist are
employed as soon as practicable to establish policy and procedures
for the service delivery. That the service manager is also
responsible for finding a suitable location for the new clinic;
organising refurbishment; and hiring and training non-medical staff.
Feasibility research results
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Part 1: The ProposalIntroduction
This report presents the results of more than four years of research
addressing the question: Should a carefully controlled and
rigorously evaluated trial be conducted to determine whether or not
the prescription of pharmaceutical heroin (diacetylmorphine1) is a
useful addition to current maintenance treatment options for
dependent heroin users?2 Two important components to this question
must be highlighted. First, the question is about the feasibility of
conducting a trial, not about the feasibility of a new treatment
option. The results of the trial will enhance significantly the
ability to assess whether or not the new treatment option should be
introduced. Second, diacetylmorphine is to be trialed as an
additional choice for dependent heroin users in current maintenance
treatment, not as a separate or replacement treatment.
It was concluded that while there are both potential benefits
and potential risks to conducting such a trial, the benefits
outweigh the risks. It is recommended that the investigation of the
feasibility of a trial now move to a third stage of pilot studies,
which should take place in Canberra.3
The research was undertaken after Mr Michael Moore MLA
approached the National Centre for Epidemiology and Population
Health (NCEPH) at The Australian National University in March 1991.
At the time, he was the Presiding Member of the ACT Legislative
Assembly Select Committee on HIV, Illegal Drugs and Prostitution.
The committee argued that “current policy implementation with regard
to controlling and/or reducing the use of illegal drugsÉmight not be
effective” (Legislative Assembly for the Australian Capital
Territory 1991:1). Members were particularly concerned about the
social costs of dependent heroin use, including the potential for
spread of HIV/AIDS, both within the illicit drug using community and
from that group into the general community. Members recognised that
“the Australian official drug strategy of harm minimisation has had
considerable success, particularly in combating the spread of HIV”
and wanted to explore “what would be the next step if the harm
minimisation approach was to be extended” (Legislative Assembly for
the Australian Capital Territory 1991:v).
During the course of the feasibility research, evidence began
to accumulate that treatment of illicit drug users is more cost-
effective than leaving them in the community untreated or sending
them to jail (see part 2). This suggests that it will be highly
advantageous to society to improve both the attractiveness and
effectiveness of treatment.
An expert committee convened by NCEPH in April 1991
overwhelming endorsed the need to examine the feasibility of
                        
1 Throughout this report, diacetylmorphine is used to refer to
pharmaceutical ‘heroin’. Heroin refers to the illicit drug.
2 Maintenance treatment in Australia is currently confined to oral methadone
treatment. Maintenance treatment is described in Part 2.
3 Canberra is the only large population centre in the Australian Capital
Territory (ACT). The terms Canberra and ACT are used interchangeably.
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expanding maintenance treatment to include diacetylmorphine and
suggested a four-stage process.
The first stage, undertaken collaboratively between NCEPH and
the Australian Institute of Criminology (AIC), found that a trial to
assess the therapeutic value of adding diacetylmorphine to the
maintenance treatment options for heroin dependence was feasible in
principle (NCEPH, 1991*4) and it was recommended that the logistic
feasibility of a trial be examined. This report marks the end of
that second stage. The results show that it is logistically feasible
to conduct a trial and it is recommended that the third stage of
pilot investigations be undertaken. If those are successful then
there should be a full-scale trial, the fourth stage.
The rationale for expanding maintenance treatment to include
diacetylmorphine is described in part 2 of this report, where the
history and context of this project are also presented. The results
of the feasibility investigations are presented in part 3 and a
budget for the pilot studies is presented in part 4.
The proposal to pilot and trial the addition of
diacetylmorphine to maintenance treatment
Proponents of adding diacetylmorphine prescribing to current
maintenance treatment argue that providing the drug
(diacetylmorphine) and route of administration (intravenous
injection) that users want would bring more dependent heroin users
into treatment, keep them in treatment longer and produce outcomes
that are better than currently available options. In particular,
proponents argue that it will mean that dependent heroin users do
not have to commit crime to buy expensive illicit heroin and that it
will remove them from the illicit drug scene, so that they no longer
use illicit heroin or other drugs. In addition, they argue that
access to pharmaceutically pure diacetylmorphine and using it in a
clinical environment will remove the health risks associated with
heroin use, including the risks of transmission of HIV/AIDS and
hepatitis. Finally, removing people from the illegal drug scene and
placing them in a treatment environment will give them time and
access to resources to allow them to become more socially
integrated.
The addition of diacetylmorphine prescribing to currently
available maintenance treatment should, if practised on a large
enough scale, attract a substantial proportion of dependent heroin
users into treatment, so that there should be measurable social
benefits. In particular, there should be a noticeable reduction in
property crime, as this is the largest social cost associated with
dependent heroin use.
The anticipated benefits on both the individual and social
levels form testable hypotheses.
Opponents of expanding maintenance treatment to include
diacetylmorphine argue that the benefits would not eventuate and
                        
4  References marked with * resulted from the feasibility research.
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have pointed to a range of risks, including that any city
introducing such an option would attract dependent heroin users from
around the country; that controlled availability of diacetylmorphine
would encourage illicit drug use; and that a trial would face
insurmountable logistic problems. Like the benefits, the potential
risks also form testable hypotheses. The assessment of the
feasibility study is that various safeguards can minimise these
risks and that the potential advantages of expanding maintenance
treatment to include diacetylmorphine should be investigated.
If pilot studies and a trial are undertaken, it is crucial that
the effects are fully and carefully evaluated so that the questions
discussed above are addressed and so that a better informed
assessment can be made of whether or not diacetylmorphine
prescribing is a useful long-term addition to maintenance treatment
for dependent heroin users.
There are three population groups of interest: dependent heroin
users who have dropped out of currently available treatment options,
current methadone clients who would prefer the expanded treatment
option and dependent heroin users who have never been in treatment.
The first two groups identify themselves as being in need of
treatment, but current options are not, or not completely,
successful. The third group includes two sub-groups. The first are
dependent users whose drug use and lifestyles are relatively stable
and who either see little need for help or do not see current
treatment services as appropriate. The second are younger users,
whose dependence is just beginning to become problematic. These are
the ‘hard-to-reach’ dependent users about whom relatively little is
known, including how useful treatment could be.
The treatment to be evaluated is not injectable
diacetylmorphine alone, instead the evaluation will examine a
treatment option which provides a choice of injectable
diacetylmorphine alone, injectable diacetylmorphine plus oral
methadone or oral methadone alone and where, within the limits of
medical safety, participants can move freely between these options.
In addition to assessing whether or not the availability of
injectable diacetylmorphine improves the ability to attract and
retain people in treatment, the major comparison for a trial will be
between participants who are allowed a choice of options which
includes injectable diacetylmorphine and participants who have only
oral methadone available to them. While a straight comparison
between injectable diacetylmorphine and oral methadone would be
methodologically neater, it is not clinically sensible. Oral
methadone treatment is available, well accepted, has advantages
particularly in terms of its long-acting nature5 and effectiveness
as an oral medication, and is a successful treatment for many
dependent users. To reiterate, the key clinical question is: if
maintenance treatment is expanded so that both injectable
diacetylmorphine and oral methadone are available, is this more
                        
5 Oral methadone is effective with a single administration daily.
Diacetylmorphine is shorter acting and most dependent users inject
more than once a day. Allowing a combination of treatments should give
participants maximum flexibility.
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effective than current maintenance treatment which involves the
provision of oral methadone only?
A strong criminological component which examines the social
impact of expanded maintenance treatment, particularly the effects
on crime, is also central to the evaluation. To monitor the
potential risks, a package of indicators of crime, public order and
justice will be developed.
Testing the hypotheses should proceed in careful incremental
steps, allowing the research to be halted if there is no indication
that the mooted beneficial results will be realised or if there are
substantial negative effects. Thus there would be two pilot studies
followed—if indicated—by a full-scale trial.
Recommendation 1. That two carefully controlled pilot studies are
conducted in Canberra to assess the addition of injectable
diacetylmorphine to maintenance treatment for registered dependent
users. If these produce positive outcomes, that a full-scale trial
of expanded maintenance treatment which includes injectable
diacetylmorphine is conducted in at least three Australian cities.
Although exploring the addition of injectable diacetylmorphine
to maintenance treatment has implications for illicit drug policy,
it must not be used as a lever to weaken law enforcement or
prevention activities against illicit drug use.
Recommendation 2. That the exploration of expanding maintenance
treatment to include injectable diacetylmorphine is coupled with
continuing law enforcement and prevention activity to control
illicit drug use. The addition of diacetylmorphine to maintenance
treatment should not be linked with permissive attitudes to illicit
drug use.
The first pilot study will assess if the addition of injectable
diacetylmorphine to maintenance treatment can be conducted in the
Australian context on a small scale. All participants will have a
choice of treatment options: injectable diacetylmorphine alone,
injectable diacetylmorphine plus oral methadone or oral methadone
alone. The focus of the pilot will be to determine if participants
can be stabilised on injectable diacetylmorphine or injectable
diacetylmorphine plus oral methadone; if participants can move
readily between the three options, so that there is flexibility in
treatment; and if a workable and appropriate clinical service can be
provided. For the second pilot study to be started, more than half
of the participants in Pilot 1 must be successfully stabilised and
there must be clear evidence of successful integration of injectable
diacetylmorphine into oral methadone treatment to provide
flexibility in treatment.
The effectiveness of the treatment will be assessed using a
variety of outcome measures namely health, including HIV/AIDS and
hepatitis risk behaviours and licit drug use; criminal behaviour,
including illicit drug use; and social functioning. In order to
evaluate the impact of the treatment for individuals, these measures
will be compared before and after participants enter the study.
Feasibility research results
19
There will have to be clear indications of effectiveness on at least
half of the outcome measures to warrant proceeding to Pilot 2.
As outlined earlier, potential positive and negative social
effects must also be measured. However, methods for evaluation at
the social level are much less well developed than examination of
individual level outcomes. This pilot will investigate development
of a package of indicators to monitor effects on all or some of:
crime levels and patterns and public perceptions of crime; illicit
drug markets, including leakage of trial drugs onto the illicit
market; drug use patterns, especially among young people; heroin
users moving to the ACT; offensive public behaviour by illicit drug
users, including the discarding of injecting equipment in public
places; effects on public health and safety, including numbers of
overdoses and drug-related motor vehicle crashes; and effects on
other treatment services, law enforcement and the ambulance service.
There will be 40 participants, with equal numbers being drawn
from current ACT methadone clients who would prefer the expanded
treatment option and from dependent heroin users who have dropped
out of methadone treatment in the ACT. There will be equal numbers
of men and women. All must have been ACT residents since at least
1993. This pilot will run for 7.75 months and effects will be
assessed over six months.
Recommendation 3. That the first pilot study is conducted with 40
established ACT resident volunteers who have either dropped out of
ACT methadone treatment or who are current ACT methadone clients who
would prefer the expanded treatment option. That, over a six-month
period, the study examines the following questions:
• can the addition of injectable diacetylmorphine to maintenance
treatment for dependent heroin users be undertaken successfully on
a small scale in the Australian context?
• can dependent heroin users be stabilised on injectable
diacetylmorphine or injectable diacetylmorphine plus oral
methadone and what are the optimum dosage ranges?
• can injectable diacetylmorphine maintenance treatment be
successfully integrated with oral methadone maintenance treatment
to provide flexibility in treatment?
• does the expansion of maintenance treatment to include injectable
diacetylmorphine improve the health and social functioning and
reduce the criminal behaviour of participants?
• is it possible to develop a package of indicators to measure the
social impact of adding injectable diacetylmorphine to maintenance
treatment?
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Recommendation 4: Pilot study 1 will be deemed a success if the
following criteria are met:
• that a stable maintenance dose of injectable diacetylmorphine or
injectable diacetylmorphine plus oral methadone is found for more
than half of the participants;
• that injectable diacetylmorphine maintenance treatment can be
successfully integrated with oral methadone maintenance treatment;
• that there are indications of improvements in at least half of the
outcome measures pertaining to health, criminal behaviour and
social functioning;
• that workable measures of social impact are determined.
Assessment that this pilot study has been a success will warrant
proceeding to pilot study 2.
An additional 210 participants will be recruited for Pilot 2,
making a total of 250 participants. Recruitment will be gradual. Up
to 100 places (80 additional places) will be available for
volunteers who are dependent heroin users who have dropped out of
methadone treatment in the ACT. One hundred and fifty places (an
additional 130 places) will be available for current clients of the
ACT methadone program who would prefer the expanded treatment
option. To be eligible, participants must have been ACT residents
since at least 1993.
One of the research questions this pilot will test is whether
or not the availability of injectable diacetylmorphine as a
treatment option can attract back into treatment dependent heroin
users who have dropped out of methadone treatment and if it can
retain them in treatment. It will also test if the retention rate
for participants recruited from current methadone treatment is
higher than if they had been left on methadone treatment. Like many
methadone programs, the ACT methadone program has a relatively high
rate of turnover. In both 1993 and 1994, half of the people who
entered the program had dropped out within a few months. For the
pilot to be deemed successful, there must be an indication that
dependent heroin users who have dropped out of methadone treatment
are attracted back to treatment and that the retention rate for both
this group and for those recruited from current methadone clients is
improved.
The 250 participants in pilot 2 will be randomly allocated, on
a one-to-one basis, to either the ‘choice’ or the ‘control’ groups.
The ‘choice’ group will have the choice of injectable
diacetylmorphine only, injectable diacetylmorphine plus oral
methadone or oral methadone only. The ‘control’ group will have only
oral methadone available. This pilot will assess whether or not a
randomised controlled trial is likely to be a successful evaluation
strategy for a full-scale trial. The highly desirable ‘choice’
option will be available to only half of the participants. If a
substantial proportion of those allocated to the ‘control’ group
refuse to participate further in the trial evaluation or drop out of
treatment completely, a randomised controlled trial will not be not
workable. If a randomised controlled trial cannot be conducted, that
would significantly weaken the ability to effectively evaluate
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whether or not the outcomes of those allocated to the ‘choice’ group
are better than those of participants allocated to the ‘control’
group in the main multi-centre two-year trial.
Pilot 2 will also assess the effectiveness of expanding
maintenance treatment for the individual participants by examining
effects on health, criminal behaviour and social functioning. The
‘choice’ and ‘control’ groups will be compared and there will also
be comparisons of participants before and after they entered the
study. Again, there must be significant indicators of effectiveness
for a full-scale trial to be instigated.
The second pilot will also test if the addition of injectable
diacetylmorphine to maintenance treatment can be conducted on a
large scale in one city. As in pilot 1, the aim will be to
determine: if participants can be stabilised on injectable
diacetylmorphine or injectable diacetylmorphine plus oral methadone;
if participants can move readily between the three options, so that
there is flexibility in treatment; and if a workable and appropriate
clinical service can be provided, with the investigation on a large
rather than a small scale. The pilot will be deemed to be a success
if more than half of the participants can be stabilised on the
available options and if there is clear evidence of successful
integration of injectable diacetylmorphine into oral methadone
treatment to provide flexibility in treatment.
This pilot will also test the feasibility of integrating a
large scale evaluation into a treatment program. It will examine
whether or not the proposed trial evaluation strategy can be
conducted without undue respondent burden and will set in place
processes so that the results can be made available in a timely
fashion. It is also likely that some new measures will be used as
part of the evaluation and this pilot will test their validity and
reliability.
This pilot will also begin to measure the package of indicators
of social effects developed in pilot 1.
Pilot 2 will take 10.25 months to conduct and will measure
effects over six months.
Recommendation 5. If pilot study 1 is a success, that a second pilot
study is conducted with 250 dependent heroin users drawn from
volunteers who have been resident in the ACT since 1993 and who have
dropped out of ACT methadone treatment or who are current ACT
methadone clients who would prefer the expanded treatment option.
That, over a six-month period, this pilot address the following
questions:
• does the addition to maintenance treatment of injectable
diacetylmorphine attract back and retain in treatment dependent
heroin users who have dropped out of methadone treatment?
• does the expansion of maintenance treatment to include
diacetylmorphine improve retention in treatment for those drawn
from current methadone clients?
• is it possible to conduct a successful randomised controlled trial
with dependent heroin users when the highly desirable ‘choice’
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option, which provides injectable diacetylmorphine, is available
to only half of the participants?
• does the addition of injectable diacetylmorphine to maintenance
treatment produce better outcomes in terms of health, criminal
behaviour and social functioning?
• can dependent heroin users be stabilised on injectable
diacetylmorphine or injectable diacetylmorphine plus oral
methadone on a large scale?
• can injectable diacetylmorphine maintenance treatment be
integrated successfully with oral methadone maintenance treatment
to provide flexibility in treatment on a large scale?
• are the individual measures of outcomes ‘workable’, in other words
can the questionnaires be administered without undue respondent
burden and can the results be analysed in a timely fashion? If new
measures are used, are they valid and reliable?
• is the package of indicators developed to measure the social
effects of a trial workable? Have there been any major negative
social effects?
Recommendation 6: Pilot study 2 will be deemed a success if the
following criteria are met:
• that there is an indication that dependent heroin users, who have
dropped out of methadone treatment, are attracted back to
treatment and that the retention rate for both this group and for
those recruited from current methadone clients is better than for
participants who receive oral methadone only;
• that the process of randomising participants into two groups, only
one of which receives the choice of injectable diacetylmorphine
prescription, is shown to be feasible for evaluating the multi-
centre two-year trial;
• that at the end of six months, there are indications of
improvements in at least half of the outcome measures pertaining
to health, criminal behaviour and social functioning;
• that a stable maintenance dose of injectable diacetylmorphine or
injectable diacetylmorphine plus oral methadone can be found for
more than half of the participants in the ‘choice’ group;
• that injectable diacetylmorphine maintenance treatment can be
integrated successfully with oral methadone maintenance treatment;
• that individual measures of outcomes are determined to be
workable;
• that the package of indicators developed to measure the social
impact of diacetylmorphine prescribing is workable and there have
been no major negative effects.
Assessment that this pilot study has been a success will warrant
proceeding to a full-scale trial.
As outlined above, the trial will focus on three population
groups—dependent heroin users who have dropped out of currently
available treatment options, current methadone clients who would
prefer the expanded treatment option and dependent heroin users who
have never been in treatment. For the first and last of these
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groups, evaluation would assess whether or not the addition of
injectable diacetylmorphine to maintenance treatment improved the
ability to attract dependent heroin users into treatment. For all
groups, there would be assessment of whether or not expanding
maintenance treatment to include injectable diacetylmorphine
improved the ability to retain participants in treatment. In
addition, there would be assessment of whether or not participants
randomly assigned to a ‘choice’ group (with options of injectable
diacetylmorphine alone, injectable diacetylmorphine plus oral
methadone or oral methadone alone) had better outcomes than
participants randomly assigned to a ‘control’ group, where only oral
methadone was available. The outcomes would again be health,
including HIV/AIDS and hepatitis risk behaviours and licit drug use;
criminal behaviour, including illicit drug use; and social
functioning.
The trial will last for two years. If the outcomes are positive
in the first year, all participants will be offered the expanded
treatment option which includes injectable diacetylmorphine in the
second year. This has three advantages. First it will test the
ability to sustain the positive effects with a larger number of
participants. In addition, there is likely to be less intense
interest in the trial in the second year and this will give a more
accurate indication of the ability to sustain positive effects in
the long term. Third, availability of diacetylmorphine in the second
year should maximise the likelihood that the ‘control’ group will
continue to participate in the trial, so that meaningful comparisons
of outcomes can be made between the ‘choice’ and ‘control’ groups in
the first year. If the results show that there is no additional
advantage to prescribing injectable diacetylmorphine over the
prescription of oral methadone alone or that expanding maintenance
treatment by prescription of injectable diacetylmorphine has value
for only a subgroup of dependent heroin users, the second year
should be used to limit or wind down the prescribing of injectable
diacetylmorphine and to gradually return those in the ‘choice’ group
to other treatment options.
For a randomised controlled trial to produce useful results
which are generalisable, it must be conducted in more than one city.
The illicit drug scene varies from city to city, as does the
provision of maintenance treatment. In addition, the results have
national implications and, if the Canberra-based pilots have been
successful, it will be appropriate to examine the research questions
more broadly. Thus, if a full-scale trial proceeds, it should be
conducted in three Australian cities. Each will limit participation
to established residents. There will be 1000 participants, with 350
drawn from dependent heroin users who have dropped out of currently
available treatment options, 350 from current methadone clients who
would prefer the expanded treatment option and 300 from dependent
heroin users who have never been in treatment. There will be at
least 100 participants from each group in each city.
The package of social indicators will measure potential
positive and negative social effects. Cost-effectiveness, as well as
effectiveness, will be measured and will take into consideration the
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ability to attract and retain people in treatment, and individual
and social effects.
Criteria for the success of the trial are not stipulated.
These should be determined before the trial is run, but in light of
experience with the pilot studies.
It is worth noting that the research questions to be addressed
by this trial are much broader than those being investigated by the
Swiss trials. The Swiss trial focus on those for whom other
treatment options have not been successful.
Recommendation 7: If the pilot studies are shown to be successful,
that a two-year trial with 1000 participants is conducted in three
Australian cities. That it target three groups of dependent heroin
users—those who have never been in treatment, those who have dropped
out of treatment, and current methadone clients who would prefer the
expanded treatment option. That it address the following questions:
• can the availability of injectable diacetylmorphine as part of
maintenance treatment attract into and retain in treatment, people
who have not previously been in treatment?
• does the addition to maintenance treatment of injectable
diacetylmorphine attract back and retain in treatment dependent
heroin users who have dropped out of methadone treatment?
• does the expansion of maintenance treatment to include
diacetylmorphine improve retention in treatment for those drawn
from current methadone clients?
• for each of the three target groups, does providing a choice of
treatment which includes the option of injectable diacetylmorphine
improve outcomes over the option of oral methadone only?
Participants in the ‘choice’ and ‘control’ groups will be compared
on the following measures: health, criminal behaviours and social
functioning. If the outcomes are positive in the first year, all
participants will be allocated to the ‘choice’ group for a second
year, to test if the positive outcomes can be sustained.
• what is the social impact of expanding maintenance treatment to
include diacetylmorphine prescription?
• is adding diacetylmorphine to maintenance treatment cost-
effective?
Although the proposal involves expanding current maintenance
treatment to include diacetylmorphine, the pilots and trial will
require the establishment of a new and separate clinic, which is
specifically tailored for the provision of this new treatment
option. Additional medical, nursing and counselling staff must also
be employed. Diacetylmorphine hydrochloride can be purchased as a
sterile powder through legal commercial channels outside Australia.
Diacetylmorphine will only be available for injection at the clinic;
there will be no take-away doses. Oral methadone will be available
as take-away doses in accordance with current guidelines. Injectable
diacetylmorphine will be available up to three times per day, oral
methadone will be available once a day. The clinic will have opening
hours in the morning, early afternoon and early evening. Doses will
be individually tailored, but, based on Swiss experience, there will
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be an upper limit of 800 mg diacetylmorphine per day. Apart from
features specific to the provision of injectable diacetylmorphine,
guidelines established for the provision of oral methadone will be
followed. There will be strict security procedures and the injection
of diacetylmorphine will be closely supervised to prevent diversion
and to ensure that safe practices are followed. Trial participants
will be assessed for their ‘fitness’ to leave the clinic and
particularly to drive a motor vehicle.
Recommendation 8. That the service provision for the pilot studies
and the ACT component of the trial is provided by the Alcohol and
Drug Service of ACT Health. That the independent evaluation is
conducted jointly by the National Centre for Epidemiology and
Population Health at The Australian National University and the
Australian Institute of Criminology. That a committee is established
to oversee the running of the pilot studies and the ACT component of
the trial. Its membership should include representatives from the
clinical staff, participants and researchers; the police and
judiciary; the medical profession and non-government treatment
services; ACT Health and the ACT Attorney-General’s Department;
relevant Commonwealth departments; and an ethicist. That this
committee will recommend to the ACT Legislative Assembly whether or
not there should be progression from pilot 1 to pilot 2 and from
pilot 2 to a trial or if the prescription of injectable
diacetylmorphine should be stopped at any time.
Conducting the pilots and trial will be require a significant
financial commitment. A number of factors contribute to the expense.
The cost of diacetylmorphine itself is relatively high, because only
small quantities are produced by limited numbers of legal commercial
producers. The need for high security during production, shipment,
storage and dispensing adds to the cost. Because diacetylmorphine
can only be administered at the clinic, there are costs associated
with staffing the treatment centre for extended hours. Ironically,
if expanding maintenance treatment by including diacetylmorphine is
successful in attracting people into treatment and in retaining
them, this will also add to the costs. Finally, high quality
evaluation is expensive.
There will be a preparatory phase which will last at least six
months; pilot 1 will take 7.75 months; pilot 2 10.25 months; and the
trial will take two years.
It is estimated that establishing and conducting an initial
six-month pilot with 40 participants will cost around $800,000 and a
second six-month pilot with 250 participants will cost $1.5 million.
Initial estimates suggest that expanded maintenance treatment which
includes diacetylmorphine would cost the community less than one-
tenth of the cost of an untreated illicit heroin user and would be
substantially cheaper than some current treatments.
Recommendation 9: That, noting the national significance of the ACT-
based pilot studies, there is extensive financial support from
outside the ACT to fund the pilot studies.
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Implementation
Although the process of developing this proposal has been highly
consultative, none of the major interest groups have seen the final
report and recommendations. There must be an opportunity for the
report and recommendations to be scrutinised, discussed and, if
necessary, modified before the proposal is implemented. Three months
should be allowed for this consultation process, which should be
overseen by a committee with representation from the Alcohol and
Drug Service, the police and judiciary, the ACT Attorney-General’s
Department, relevant Commonwealth departments, illicit heroin users,
the medical profession and non-government treatment services, an
ethicist and the Director of the Feasibility Research. The
consultation process should end on 30 September 1995 and the
committee should report to the Minister for Health in the ACT on the
results of the process by 31 October 1995.
Recommendation 10: That the ACT government institutes a three-month
consultation period in which the results of the feasibility research
are widely disseminated and discussed. That a committee is
established to receive and consider the feedback from groups and
individuals. That the committee includes representation from the ACT
Health Alcohol and Drug Service; the police and judiciary; the ACT
Attorney-General’s Department; relevant Commonwealth departments;
illicit heroin users; the medical profession and non-government
treatment services; an ethicist; and the Director of the Feasibility
Research. That the committee reports to the ACT Minister for Health
on the results of the consultation no later than 31 October 1995.
Immediate steps must be taken to minimise the possibility of
illicit heroin users from around Australia moving to the ACT. The
ACT Health Alcohol and Drug Service should write to drug treatment
and user advocacy groups around Australia informing them of the
current status of considerations about the pilot studies and of the
eligibility criteria, so that dependent heroin users will be aware
that moving to the ACT will not give them access to the pilots or
trial.
Recommendation 11: That the ACT Health Alcohol and Drug Service is
proactive in disseminating information about eligibility criteria to
drug treatment services and user advocacy groups around Australia.
Recommendation 12: That, to establish the first pilot study, the ACT
Legislative Assembly either amend existing legislation or introduce
special legislation to make diacetylmorphine available for carefully
controlled and limited medical prescription. That the ACT government
liaise with the Commonwealth and other States about the passage of
relevant legislation and the provision of the necessary licences and
permissions. That a service manager and a senior specialist are
employed as soon as practicable to establish policy and procedures
for the service delivery. That the service manager is also
responsible for finding a suitable location for the new clinic;
organising refurbishment; and hiring and training non-medical staff.
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Part 2: The rationale for expanding maintenance
treatment to include diacetylmorphine and the
history and context of the feasibility
researchThe Rationale for Expanding Maintenance
Treatment to include Diacetylmorphine
It is beyond the scope of this report to reiterate the history of
government responses to the use of heroin and other psychoactive
drugs (excellent reviews are available in Manderson 1993 and Musto
1987) or to examine critiques of that response (there are many; eg
see Fox and Matthews 1992; Kaplan 1983; Rainforth 1991*). Suffice to
say that there have been strenuous national and international
efforts which have made heroin use illegal and maintained this
illegality.
Both nationally and internationally, there is long-standing and
continuing government and public concern about the use of mood-
altering drugs in which the use of heroin looms large. In Australia,
since 1971, there have been at least ten Royal Commissions,
Committees of Inquiry or Parliamentary Committees which have dealt
with drugs, drug use and ways of ameliorating the effects of drug
use. Since 1979 these enquiries have considered the option of
diacetylmorphine maintenance treatment, and although they have
recommended against it (with some suggesting that the prescription
of diacetylmorphine may have value for a small number of dependent
users), the issue has persisted (Hartland 1991*; Hartland et al.
1992*).
There has been international as well as national interest in
diacetylmorphine maintenance treatment. In 1994, the Swiss
government began trials of diacetylmorphine maintenance treatment
for heroin dependence and in mid-June 1995, the Health Council of
the Netherlands recommended that Dutch trials should be undertaken.
Diacetylmorphine maintenance prescription for heroin dependence
continues to be a treatment option in the United Kingdom, although
it is no longer as widely practised as it was in the 1960s and
1970s. A randomised controlled trial conducted in the 1970s to
assess the value of the, then, new methadone maintenance treatment
against that of the, then, established diacetylmorphine maintenance
treatment produced equivocal results. Hence debate continues.
Serious consideration was also given to the prescription of
diacetylmorphine in the USA in the 1970s, but political
considerations prevented a trial from eventuating (Working Paper A
in preparation).
The arguments against diacetylmorphine maintenance prescribing
are not presented here. The arguments and their analysis form a
substantial proportion of Part 3 of this report.
There are a number of reasons for the persistence of this
issue. First, the arguments put by proponents have not been properly
tested. These arguments have been outlined in Part 1, but are
basically that expansion of maintenance treatment to include
diacetylmorphine will have beneficial effects for individual
patients and will ameliorate some of the social problems caused by
dependent use of illegal heroin.
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Changing conditions have also given impetus to the prospect of
expanding maintenance treatment to include diacetylmorphine. The
advent of HIV/AIDS has been particularly potent. Concerns about its
transmission through the intravenous drug using community and fears
that the intravenous drug using community might be a conduit for the
spread of the disease into the general population have led to
consideration and implementation of a range of preventative options,
one of which is to add diacetylmorphine to maintenance treatment.
Most recently, evidence about the cost-effectiveness of
treatment has begun to accumulate and has spurred thinking about new
treatment possibilities. In 1991 the National Institute on Drug
Abuse in the USA collated evidence from a number of studies to show
that treatment of illicit drug users is more cost-effective than
leaving them in the community untreated or sending them to jail. The
untreated dependent user was estimated to cost society $US43,000 per
year, imprisonment costs $US40,000 per year, whereas methadone
treatment costs $US3,500 per year and treatment in a therapeutic
community costs around $US16–20,000 per year (National Institute on
Drug Abuse 1991).
A study of Californian drug and alcohol treatment showed that
the benefits of treatment outweighed the costs by ratios of 4:1 to
12:1, depending on the type of treatment (Gerstein et al. 1994). The
estimated cost to tax-paying citizens of a dependent heroin user in
the year before entering methadone maintenance treatment was
$US19,334, with about one-quarter being the value of cash and
property stolen.
Australian evidence is comparable, except that the costs to the
community before a dependent user enters treatment are estimated to
be substantially higher. A study commissioned by the therapeutic
community Odyssey House in Victoria estimated that the cost to
society of a dependent user in the year before entering the
therapeutic community is $A75,000, with $A53,000 being the cost of
drug-related crime. The study also estimated that incarcerating
dependent users costs $A48,000 and that treating them at Odyssey
House costs $A15,600 per year (Odyssey House, no date). Calculations
based on preliminary results from a South Australian study, estimate
the cost of criminal activity (excluding drug dealing) at $A130,000
per year before a dependent user enters methadone treatment and that
methadone treatment costs just over $A2,000 per year (Ryan et al.
1995; Jason White, personal communication 1995).
The budget for the clinical service in pilot 2 suggests that
expanding maintenance treatment to include diacetylmorphine would
cost a maximum of $10,000 per participant per year (see Part 4).
This is about one-tenth the cost to the community of an untreated
dependent heroin user. Although it is substantially more expensive
than methadone treatment, there is a much higher component of
counselling and social support.  The cost is significantly less than
that of a therapeutic community.
Currently, the main forms of treatment for heroin dependence
are methadone maintenance, detoxification, counselling and
therapeutic communities (and combinations of these). The
introduction of methadone maintenance treatment by Dole and
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Nyswander in the 1960s marked a significant advance. In a review of
evaluations of methadone treatments in 1992, Ward and colleagues
concluded that “methadone maintenance is the best of the available
alternatives. Other forms of treatment attract and retain fewer
patients, and do not produce superior outcomes among those who
complete treatment” (p. 285). However, they also pointed out that
methadone treatment is not a panacea. On average, within 12 months,
about half of those who enter methadone treatment either leave or
are discharged (many programs have sanctions against continuing
illicit drug use). Methadone programs also vary in their
effectiveness in reducing criminal behaviour, including illicit drug
use. Finally, the benefits of methadone maintenance continue only as
long as the person remains in treatment; relapse to heroin use is
high for those who discontinue treatment. There is little research
evidence on either the proportion who eventually become drug-free or
of the success of planned withdrawal and rehabilitation.
This evidence suggests that there is merit in investigating
other drugs to determine if they can, like methadone, meet the
following criteria for effective maintenance treatment:
• there should be cross tolerance and cross dependence with the
psychoactive substance causing dependence
• the drug should reduce craving and suppress withdrawal
• administration of the drug should result in stabilised consumption
(within a defined therapeutic range)
• it should result in improvement in physical health
• it should facilitate psychosocial wellbeing with an emphasis on
habilitation and rehabilitation
• it should be acceptable to clients
• it should be acceptable to professionals
• it should be acceptable to the general community
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• there should be no long-term toxic effects resulting from
therapeutic administration
• it should be both affordable and available for use.
(These draft criteria were proposed at a Program on Substance Abuse
Consultation on the World Health Organization Drug Substitution
Project in Geneva in May 1995 [proceedings forthcoming].)
Possible candidates for expanded maintenance therapy include
buprenorphine, LAAM (levomethadyl acetate), naltrexone, injectable
methadone and diacetylmorphine. The feasibility study originally
intended to consider a range of opioids, but at the end of Stage 1
narrowed the field to diacetylmorphine. This option has been the
most discussed but least researched and is a highly-preferred option
for most dependent heroin users.
The criteria listed above in essence reword the research
questions which the pilots and trial have been designed to explore.
The pilot studies will address the question of whether or not
administration of diacetylmorphine or diacetylmorphine plus oral
methadone can result in stabilised consumption (within a defined
therapeutic range).
The trial will examine effects on physical health, psychosocial
wellbeing (habilitation and rehabilitation) and affordability.
The research to date has established acceptability, at least in
principle, to clients, professionals and the general community (see
Part 3) and the known properties of diacetylmorphine meet the
criteria of cross tolerance and cross dependence, elimination of
craving and withdrawal, and no long-term toxicity.
However, as the discussion above shows, questions about
assessment of the therapeutic value of diacetylmorphine are asked in
a highly politicised context and the issues which need to be
addressed in a feasibility study encompass a range of topics not
normally weighed in the balance when deciding whether or not to
trial a drug clinically. These issues include the legal status of
prescribing the drug and an assessment of social risks, including
the dangers of escalating non-therapeutic use of the drug and of
attracting dependent heroin users to the city where the trial is to
be conducted.
This feasibility study is a systematic in-depth examination of
the scientific, clinical and political issues involved in a trial of
expanding maintenance treatment to include diacetylmorphine
prescription. It concludes that diacetylmorphine maintenance
treatment may be a valuable addition to current treatment options
and thus that its efficacy should be trialed and carefully
evaluated. There must be appropriate safeguards against the likely
risks. The proposed trial will address long-standing questions about
whether adding diacetylmorphine to maintenance treatment is an
effective additional treatment option or has no value and should be
abandoned.
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A Brief History of the Feasibility Study
As outlined above, there is a sixteen-year history in Australia of
government consideration of the issue of diacetylmorphine
maintenance treatment. In 1989, the newly formed ACT Legislative
Assembly established a Select Committee on HIV, Illegal Drugs and
Prostitution. It had representatives from both the Labor and Liberal
parties and was presided over by Mr Michael Moore, then a member of
the Residents’ Rally and later an independent member. As part of its
deliberations the committee examined the issue of diacetylmorphine
maintenance treatment.
In March 1991, the Presiding Member approached the Director of
NCEPH, Professor Bob Douglas, to discuss the possibility of a trial
of such treatment. In April a group of experts in drug treatment and
drug policy assembled at NCEPH, endorsed the need for a study into
the feasibility of diacetylmorphine maintenance treatment and
suggested a four-stage process. Each stage was to be self-contained,
ending with a decision about whether or not to proceed further. The
first stage was to consider the issue of feasibility in principle;
the second to consider logistic feasibility; the third to pilot
procedures; and the fourth stage was to be the trial itself.
Stage 1 was completed in three months, with a recommendation to
proceed to Stage 2 being made at the end of July 1991. This report
ends the Stage 2 research and recommends that two Stage 3 pilot
studies are undertaken. The Stage 1 and 2 research was undertaken
jointly by NCEPH and AIC.
Volume 1 of the Stage 1 report was reprinted in full in the
Second Interim Report of the Select Committee on HIV, Illegal Drugs
and Prostitution (Legislative Assembly of the ACT 1991), which was
presented to the ACT Legislative Assembly in August 1991. Debate on
the report was rapidly adjourned and the committee lapsed after the
ACT Legislative Assembly elections in February 1992.
In April 1992, the then Minister for Health, Mr Wayne Berry,
took the issue of the feasibility study to the Ministerial Council
on Drug Strategy (MCDS). MCDS is comprised of two Ministers, one
each from health and law enforcement, from each jurisdiction (the
Commonwealth and each Australian state and territory). MCDS noted
“the progress made by the National Centre for Epidemiology and
Population Health (NCEPH) in undertaking a feasibility study, not
involving the distribution of any drugs, into heroin treatment
options” and recommended that “the results of the feasibility study
be reported to MCDS”. In subsequent years progress reports about the
study were noted and in 1994 a subcommittee of the National Drug
Strategy Committee (NDSC) was established to consider the Stage 2
report when it was released. NDSC is a similarly representative
committee of senior officers (public servants and police), which
supports MCDS. This committee has overall responsibility for the
implementation of Australia’s national drug strategy.
NCEPH and AIC decided to proceed with the Stage 2 feasibility
research after strong support at a one-day national seminar “Heroin
Treatment—New Alternatives” in November 1991 (Bammer & Gerrard
1992*). The decision was made possible by a peer-reviewed
Feasibility research results
32
competitive grant of $445,000 over five years from The Australian
National University’s Strategic Development Fund, which aims to
“identify and develop new areas of research perceived as
particularly fruitful, in the national interest and inadequately
addressed elsewhere in the country”. A further $115,000 was raised
through other competitive peer-reviewed grants to fund a number of
specific sub-projects. (A list of grants is presented at the end of
the report.) In total the feasibility research has cost close to $1
million.
The complexity of the issues and the lack of already available
information on which to base decisions meant that the Stage 2
research took longer than originally anticipated. Making final
recommendations was postponed more than once, so that the issues
could be properly considered. This final Stage 2 report and
recommendations will be presented to the current ACT Minister for
Health, Mrs Kate Carnell (who is also the Chief Minister), on 27
June 1995 and it is anticipated that she will present the findings
to the Ministerial Council on Drug Strategy.
The Process of Conducting the Feasibility
Research
The Stage 2 research into logistic feasibility had three components:
an assessment of risks, development of a proposal for service
provision and development of a proposal for evaluation. Much of the
research broke new ground.
The process was guided by a nineteen member Advisory Committee
which met three times in 1992 and annually thereafter. The Committee
had Australia-wide representation from academics, advocates for
illicit drug users, judiciary, police, policy makers, and treatment
service providers. In order to ensure that a balance of views was
represented on the Advisory Committee, it was agreed at the outset
that the Committee would not be asked to formulate or endorse the
final recommendations.
As discussed in more detail below, there was emphasis on an
open, consultative process. As sub-projects were completed, the
results were published as working papers, so that they were
available for scrutiny and discussion. Newsletters summarising the
research results and providing updates of political events
surrounding the feasibility considerations were published from time-
to-time. Key decision makers, locally, nationally and
internationally, were briefed about results and asked for input. The
media was kept informed about the study and there were numerous
radio, television and newspaper reports. The ABC current affairs
series Attitude produced a program about the feasibility study which
was screened in June 1994. Papers were also presented at national
and international conferences and are being published in peer-
reviewed journals. One of the study aims is to facilitate informed
debate about the issues.
There was also considerable interchange of information with
Swiss policy makers, health professionals and researchers who are
involved in the trials of diacetylmorphine maintenance prescribing
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which began in 1994. The Swiss trials strongly influenced the
proposal for service provision.
Three principles guided the conduct of the feasibility study:
• the research should have intrinsic value, so that regardless of
whether or not a trial goes ahead, the research should be of value
to treatment services or to drug policy generally
• research should be conducted in all relevant disciplines and the
disciplinary findings should be integrated to address the central
problem
• the process should involve to the greatest extent possible the key
interest groups—illicit drug users, service providers, police,
policy makers and the community.
The first principle meant that research questions were framed
broadly, so that the issues relevant to the feasibility
investigations were embedded in a wide context, which provided
valuable information in itself, but also enriched the information
needed for the feasibility considerations. This can be illustrated
by three examples: the study of ex-users, the study of unmet needs
and the studies of the illicit drug market.
For the feasibility research, the study of ex-users had three
purposes—to determine whether or not ex-users supported a trial of
expanding maintenance treatment to include diacetylmorphine and why;
to try to establish whether or not there was a risk that such a
trial would make it harder for dependent heroin users to become
abstinent; and to try to establish if there was a risk that a trial
would tempt ex-users to start using again. These questions were
embedded in a study about stopping dependent use—why people had
stopped, how they had stopped and how they had maintained
abstinence. This was the first Australian study of its kind and
pointed to ways in which drug treatment might be more successfully
geared towards attaining abstinence (Bammer & Weekes 1993* 1994*).
Another important consideration for the feasibility research
was the views of those who were potential participants—were they
interested in participating and how would they want a trial to be
run? These feasibility research questions were set in the context of
unmet needs for treatment. Information was gathered on why dependent
heroin users do and do not enter treatment, whether treatment needs
are met successfully and why users drop out of treatment. Again this
study has many unique aspects and the results can help improve
existing treatment services (Working Paper B in preparation).
Understanding the drug market is important to the feasibility
study for both risk assessment and for potentially measuring trial
outcomes. The feasibility research brought together academic
researchers, police, and law enforcement intelligence analysts to
discuss ways in which data sources and skills could be better shared
in order to improve understanding of illicit drug markets (Bammer
1993b*). In addition, the feasibility research examined new ways in
which the illicit drug market could be monitored, including an
examination of fatal and non-fatal heroin overdoses (Bammer and
Sengoz 1994* 1995*; Bammer et al. 1995c*).
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The second principle involved integrating a multi-disciplinary
approach. Academic colleagues with a range of disciplinary skills
donated time to the project—the disciplines covered included
anthropology, clinical science and health care, criminology,
demography, economics, epidemiology, law, pharmacology, philosophy,
political science, policy analysis, psychology, sociology, and
statistics.
The third principle was to involve the relevant interest
groups. Martin (1991*) analysed the role of interest groups in
shaping debates about drug policy and in determining the issues and
arguments brought to bear. The aim here was primarily to use
interest groups to ensure that all potential issues, especially
risks, had been identified and to determine the level of support for
a trial of expanded maintenance treatment to include
diacetylmorphine prescribing.
Both formal and informal consultation processes were used. The
formal processes were surveys, a reference group and workshops. The
informal process was discussion, both one-to-one and small group.
The key interest groups consulted were the general community, the
police, illicit drug users, service providers, ex-users and policy
makers.
ACT community surveys were conducted in 1991 and 1994; Sydney
and Queanbeyan residents were surveyed in 1991; and a national
survey was conducted in 1995. There were also informal discussions
with individuals and particular community interest groups including
Drugs in the Family (a self-help group of, predominantly, parents of
illicit drug users) and the Victims of Crime Assistance League
(VOCAL ACT Inc).
The police were surveyed in 1991, were involved in a workshop
about drug markets in 1992 and in a workshop specifically on
policing issues for a trial in 1994. There were regular discussions
with the ACT Drug Squad and the Australian Bureau of Criminal
Intelligence. There were also discussions with the Australian
Federal Police Association (Federal and ACT branches) and individual
ACT and interstate police.
Illicit drug users in and out of treatment were surveyed in
1991 and 1993. A reference group of people who are advocates for
illicit drug user interests (without necessarily being users or ex-
users themselves) was also consulted regularly and there were many
informal discussions with individuals and advocacy groups, locally
and interstate. There was also participation in public meetings
organised by the ACT Intravenous Drug Users League (ACTIV) and the
Dependency Care Foundation.
Service providers were surveyed in 1991 and attended workshops
on medical issues involved in prescribing diacetylmorphine in 1994,
cost considerations for service provision in a trial in 1994, and
the contribution of childhood sexual abuse to alcohol, heroin, and
other drug problems in 1993. There were a number of discussions with
staff from the ACT Health Alcohol and Drug Service and staff from
non-government organisations, particularly Assisting Drug Dependants
Inc and the Alcohol and Drug Foundation of the ACT. There were also
discussions with the Australian Medical Association, the Australian
Feasibility research results
35
Salaried Medical Officers Federation and individual doctors,
pharmacists and other health professionals.
Some service providers are also ex-users and so contributed to
both perspectives. Other ex-users were surveyed in 1991 and 1993 and
there were also informal discussions.
While a highly consultative process has been used in the
formulation of this final report and recommendations, none of the
above groups has yet seen the report and recommendations and all
wanted an opportunity to consider and comment on them. It is
therefore recommended that there is a three-month consultation
period before the ACT Legislative Assembly makes a decision about
whether or not to proceed (Recommendation 10).
The Context of the Feasibility Research
This proposal must be viewed in terms of the Australian and
particularly the ACT context of illicit drug use. Australia has a
population of around 17.5 million. The ACT is a landlocked territory
surrounded by the state of New South Wales and houses the national
capital, Canberra, with a population of about 300,000. Canberra
adjoins the New South Wales city of Queanbeyan, with a population of
some 25,000. Compared to the rest of Australia, the ACT population
is younger, better educated and more affluent. Unemployment is lower
than elsewhere in Australia and more than half of the workforce is
employed in the public sector, compared to less than one-third
nationally (see Stevens et al. 1991*). An outline of factors which
might influence movement into and out of Canberra is presented in
Bammer and colleagues (1994a*).
The tangible and intangible economic costs of illicit drug use
in Australia in 1988 were conservatively estimated at $1,441
million, which is ten per cent of the costs of all drug use
(including alcohol and tobacco; Collins & Lapsley 1991).
The 1993 National Drug Household Survey (National Drug Strategy
1993) found that 34 per cent of those aged 14 years or older had
ever tried marijuana, with 13 per cent having used in the last 12
months. The next most commonly used illicit drugs were the
amphetamines with eight per cent having tried them and two per cent
having used in the last 12 months. Heroin and cocaine/crack use were
comparable with two per cent having ever tried and one per cent
having used in the last 12 months. Many dependent users in the ACT
use a range of drugs, but for a substantial proportion heroin is the
drug of choice (Stevens et al. 1991*; Bammer & Crawford 1991*;
Working Paper B in preparation). Injection is by far the most common
route of administration of heroin, but smoking and other forms of
inhaling (“chasing the dragon”) also occur (Australian Bureau of
Criminal Intelligence 1995; Stevens et al. 1991*; Bammer & Crawford
1991*; Working Paper B in preparation).
In 1988 there were estimated to be 30,000—50,000 dependent
heroin users in Australia (National Campaign Against Drug Abuse
1988). Estimates conducted as part of the feasibility study vary
somewhat, but suggest that there are likely to be around 1,000
dependent heroin users in the ACT (Larson 1992*; Larson et al.
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1994*; Larson & Bammer 1995*; Stevens et al. 1991*). A 1991 ACT
school survey of students’ drug use found that three per cent of
males and four per cent of females had ever used opiates (ACT
Government Alcohol and Drug Service 1991). In a survey of 155 ACT
people aged 12 to 17 who, because of family problems, were living
away from home or had lived away from home in the last 12 months,
eight (5%) had ever used heroin, mostly only once or twice, and none
would have been eligible for inclusion in a trial (Sibthorpe et al.
1993*)
A series of vignettes about the range of lifestyles of illicit
drug users in the ACT was presented in Stevens and colleagues
(1991*). This illustrated that while some users fit with the common
stereotype of alienated individuals with problematic lifestyles,
others are well integrated into mainstream society. The surveys
conducted as part of the Stage 2 research attracted few users who
were not in treatment, and they were generally not typical of the
stereotyped image (Working Paper B in preparation). As is expected
from the results of other methadone programs (Ward et al. 1992), a
proportion of methadone clients were still using illicit drugs and
committing crime (Bammer et al. 1994b*; Working Paper F in
preparation).
According to the Australian Bureau of Criminal Intelligence
(1995), heroin is “usually encountered as a white powder known as
No. 4 heroin, indicating a high purity product”; however, other
forms are also available. In 1994 the Australian Customs Service
reported 56 seizures of heroin, totalling around 248.5 kg. In the
same year, the price of a street gram of heroin in the ACT ranged
from $50 to $500.
Sydney, the largest city in Australia, is 300 km from Canberra,
a three to four hour drive, and is the main source of supply for
heroin in the ACT. The ACT drug market seems to have well-
established and effective systems of operation, with a high degree
of flexibility and adaptability that makes law enforcement
difficult. Eleven ACT drug dealers were in prison in 1993 (Bammer &
Sengoz 1994*).
Nationally, in 1991 7.5 per cent of prisoners had a drug-
related charge as their most serious offence, with almost six per
cent having drug trafficking as their most serious offence
(Department of Health, Housing and Community Services 1992).
Attempts to estimate the percentage of other crimes which are drug-
related are fraught with difficulties (Australian Bureau of Criminal
Intelligence 1995). However, many Australians feel that they have
been affected by drug-related crime. In the 1991 survey of the ACT
community, 25 per cent reported that they or someone close to them
had been affected by a crime that they thought was committed by
illegal drug users (Bammer & Crawford 1991*; Bammer et al. 1995b*)
and similar percentages were reported in the 1994 ACT and 1995
national surveys (Working Paper C in preparation).
Otherwise, as far as the general community is concerned, there
is little visible evidence of illicit drug use in Canberra. There
are no congregations of illicit drug users and no areas that
ordinary citizens are advised to avoid. There are, however, some
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areas of public housing that are seen to be undesirable and an
association with illicit drug use is one reason for this. It is rare
for discarded injecting equipment to be found in public places,
although a Needle and Syringe Exchange Program distributes around
130,000 needles and syringes per year. Public health measures, such
as disposal shutes for injecting equipment in some public toilets, a
mobile bus that provides AIDS education, including free condoms and
needle and syringe exchange, and various centres that provide
information, advice and other services or treatment are discreet and
well tolerated (Bammer et al. 1994a*).
In 1991, just over 3,000 people in Australia were notified AIDS
cases; five per cent were attributed to intravenous drug use
(National Campaign Against Drug Abuse 1992). The seroprevalence of
HIV infection among intravenous illicit drug users is low (under
5%), but Hepatitis B and C prevalence is high (around 70% or more;
discussed in Bammer et al. 1994a*). In 1990 there were 457 opiate-
related deaths in Australia (National Campaign Against Drug Abuse
1992). From 1988-1991 there were three deaths from accidental opioid
poisoning in the ACT and between August 1990 and July 1993 there
were an estimated 36 non-fatal heroin overdoses attended by the ACT
Ambulance Service (Bammer & Sengoz 1994*; Bammer et al. 1995c*).
A national census of drug treatment service agencies conducted
in 1992 identified 465 treatment agencies (National Campaign Against
Drug Abuse 1992). In 1991 there were more than 9,500 people on
methadone programs nationally (Department of Health, Housing and
Community Services 1992). In the ACT a range of government and non-
government agencies provide treatment and/or support for illegal
drug users. When the feasibility research began in 1991, the
government-run oral methadone program had 100 places (85 on
maintenance and 15 on withdrawal regimens) and the waiting period
for entry was about two months. During the Stage 2 research, the
methadone program underwent a period of expansion; when the surveys
of methadone clients were conducted in 1993, there were around 260
people on the program and by the end of Stage 2 the program had
reached the projected limit of expansion with 350 clients. There are
now plans to increase dispensing through pharmacies and to introduce
prescription through private general practitioners. Other treatment
services include a therapeutic community, counselling,
detoxification centres and a range of self-help groups. There are
also half-way houses and referral and information services (based on
Stevens et al. 1991*, which gives a fuller description of the ACT
situation in 1991). The ACT also has active advocacy groups both for
drug treatment clients and for illicit drug users outside treatment—
the ACT Intravenous Drug Users League (ACTIV), the Dependency Care
Foundation and Methadone Action Consumer Empowerment.
As this description of context shows, the feasibility research
has contributed to the understanding of illicit drug use in the ACT.
The main results from the feasibility research are presented in Part
3.
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Part 3: Results of the feasibility research
The Stage 1 feasibility research found that expanding maintenance
treatment to include diacetylmorphine was feasible in principle. The
Stage 2 research found that it is also feasible logistically.
The key results of the Stage 1 research are reiterated here,
along with the results of the Stage 2 research. The following issues
are covered: the level of support among a range of interest groups
for a trial of expanding maintenance treatment to include
diacetylmorphine; an examination of the legal aspects of a trial; an
assessment of the risks associated with a trial and how the risks
could be minimised; the development of a proposal for the service
provision aspects of a trial; and the development of a proposal for
evaluation. The Stage 1 and Stage 2 research also increased
understanding about illicit drug use in the ACT; these results are
presented in Part 2.
Throughout this section, the discussion does not generally
differentiate between the pilots and the trial; the same concerns
are usually relevant to both, but for the sake of brevity reference
is only made to the “trial”.
1. Support for a trial among different interest groups
The most important group is the general community. The
Canberra, Sydney and Queanbeyan communities were surveyed as part of
the Stage 1 research. The Canberra community was surveyed again in
considerable detail towards the end of Stage 2 and subsequently
there was a national survey. In Stage 1, four other key groups were
surveyed: police, providers of treatment and other services to
illicit drug users, illicit drug users and ex-users. There was
further research with both users and ex-users in Stage 2 and, during
this Stage, the views of the local Aboriginal community were also
sought. In Stage 1 there was an analysis of the views of the main
political parties which is not reported here (Hartland 1991*).
The general community
Overall, there is support in the general community for a
“heroin trial”. There is substantial support in the ACT and this
support has been sustained over time. The Australian community
generally supports the idea of prescribing through special clinics,
but there is a level of uncertainty about an ACT based trial,
although there is more support than opposition to it. Opinion is
fairly evenly divided between those who support, oppose and are
uncertain about trials of diacetylmorphine prescribing in their own
states, although there is more opposition than support. There is
clear opposition to divorcing maintenance treatment which includes
diacetylmorphine from an ultimate goal of abstinence.
In 1991 the following question was put to a random sample of
the Canberra, Sydney and Queanbeyan communities (as well as police,
service providers and users and ex-users—see below; Bammer et al.
1995b*; Bammer & Crawford 1991*), and the question was asked again
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of a Canberra sample in late 1994 (see Table 1; Working Paper B in
preparation):
Some people think there are so many problems caused by illegal
drug use that something new urgently needs to be tried. They would
say that a proposed trial should go ahead.
Other people think setting up a trial is just too risky because
it might make the problems even worse. They would argue that it
should not go ahead.
Do you think the trial should go ahead or that a trial should
not go ahead?
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Table 1
Canberra 1991
%
Canberra 1994
%
Sydney  1991
%
Queanbeyan 1991
%
go ahead 66 (62,70)6 54 (50,58) 58 (54,62) 43 (36,50)
not go ahead 27 34 34 46
don’t know 7 12 8 10
N 516 664 520 212
response rate 77% 52% 61% 74%
type of survey telephone mail telephone telephone
The responses for the Sydney and Queanbeyan samples are for a
trial in Canberra. Forty-four percent of both Sydney and Queanbeyan
respondents supported a Sydney-based trial (48% opposed in Sydney
and 47% in Queanbeyan; Bammer et al. 1995b*).
In the 1994 Canberra and 1995 national study, questions about
support for a trial were asked in a variety of ways and the level of
support varied depending how the question was asked (Table 2). The
national survey results are based on the first 1,915 responses to
questions included in the 1995 Australian component of the
International Social Science Survey. Five thousand questionnaires
were mailed out, but the survey was not finished when this report
was written. Detailed results for the Canberra and national surveys
are presented in Working Paper C in preparation.
The questions were:
Question A (after a series of detailed questions about a trial)
Now that you have heard about some of the potential
benefits and potential problems of a heroin trial in the
ACT, is your reaction to itÉ
Question B
É, what do you think about these different policiesÉ
A policy with heroin available to addicts in treatment,
but only at specific clinics; otherwise laws against
heroin use enforced as at present
Question C
Now we’d like to ask about different kinds of treatment
programs that try to deal with heroin addictsÉ
b. In a second kind of program, addicts
• visit a medical clinic regularly for counselling, and
they can take a drug to stop heroin craving if they want,
but
                        
6 The 95 per cent confidence intervals for the percentages supporting the
trial are presented in brackets throughout. This means that if the
survey had been repeated independently there is a 95 per cent chance
that the support reported would have fallen within the values in
brackets. The confidence intervals have not been adjusted for possible
bias because of differences between those who did and did not respond
to the survey. However, as is discussed in the original papers, this
bias is generally thought to be low.
Feasibility research results
41
• can also choose to get a safe, legal injection of
heroin, as often as three times a day to keep them in
the program.
• The aim is to get addicts to lead a normal, healthy
life—to have a regular job, support their family, not
break the law—
• and EVENTUALLY to get them to stop using heroin.
How do you feel about this programÉ
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Question D
In another kind of program, addicts
• visit a medical clinic regularly for counselling, and
they can take a drug to stop heroin craving if they want,
but
• can also choose to get a safe, legal injection of
heroin, as often as three times a day to keep them in
the program.
• But the program does not try to get addicts to give
up heroin;
• instead its aim is just to get them to lead a normal,
healthy life with a regular job, support their
family, and not break the law.
How do you feel about this programÉ
(There were some wording changes between the ACT and national
surveys.)
Table 2
Support trial
%
Oppose trial
%
Don’t know
%
Question A:
Canberra 62 (68,65) 17 21
Question A:
National 41 (38,43) 30 29
Question B:
Canberra 58 (54,61) 25 18
Question B:
National 57 (55,59) 24 19
Question C:
Canberra 39 (35,42) 25 37
Question C:
National 36 (34,38) 27 37
Question D:
Canberra 11 (9,13) 61 28
Question D:
National 18 (17,20) 49 33
It can be seen that a high percentage of respondents were
undecided. Of those who felt able to make a decision, a higher
percentage supported a trial than opposed it (Table 3), except for a
program which did not have abstinence as the ultimate aim (Question
D).
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Table 3
Support trial
%
Oppose trial
%
Question A:
Canberra 78 22
Question A:
National 58 42
Question B:
Canberra 70 30
Question B:
National 70 30
Question C:
Canberra 61 39
Question C:
National 57 43
Question D:
Canberra 15 85
Question D:
National 27 73
Grants
44
In the national survey, 34 per cent (32,36) supported a trial
occurring in their own city, 39 per cent were opposed to a trial in
their own city and 27 per cent were undecided. The results for
supporting an ACT trial (Question A, above) and for supporting a
trial in their own city are presented by state in Table 4.
Table 4
New South
Wales
%
Victoria
%
Queenslan
d
%
Western
Australia
%
South
Australia
%
Tasmania
%
Northern
Territory
%
ACT
%
support
for an ACT
trial
41
(37,45)
46
(41,51)
31
(25,37)
40
(32,48)
42
(34,50)
35
(25,45)
35
(24,46)
49
(38,60)
opposition
to an ACT
trial
32 25 38 29 27 28 43 26
undecided 27 30 31 31 31 37 22 25
N 527 437 204 154 137 91 77 81
support
for a
trial in
their own
city
35
(31,39)
38
(34,42)
23
(18,29)
38
(30,46)
36
(28,44)
17
(9,25)
23
(14,32)
53
(42,64)
opposition
to a trial
in their
own city
41 35 46 33 36 44 55 26
undecided 24 27 31 29 29 39 22 21
N 522 430 222 150 136 88 78 81
Views about other policy and treatment options were also
examined. In particular, policy questions from the 1993 National
Drug Household Survey were repeated (National Drug Strategy 1993).
Similar results were obtained to questions about support for the
personal use of heroin being made legal and increased penalties for
the sale/supply of heroin. Across all surveys, there is little
support for legalisation of personal use and strong support for
increased penalties for sale and supply of heroin (Table 5). The
similarity in responses between the National Drug Household Survey
and the ACT and national surveys conducted as part of the
feasibility research increases the confidence in the feasibility
study results indicating support for a trial. It also suggests that
attitudes to one policy option cannot be extrapolated to other
policy options.
Table 5
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Legalise personal use Increase penalties for
sale/supply
NDS
1993
%
Canberra
1994
%
National
1995
%
NDS
1993
%
Canberra
1994
%
National
1995
%
support 8 9 10 87 85 91
oppose 87 80 82 8 7 6
don’t know 6 11 8 4 8 3
The ACT and national surveys also found that more than 80 per
cent of respondents supported methadone maintenance treatment and
therapeutic communities (Working Paper C in preparation).
Stepwise logistic regression on the data from the 1991
Canberra, Sydney and Queanbeyan surveys showed that those who
supported a trial were more likely to be aged 30–39; to have more
years of formal education; to not be currently practising a
religion; to know someone close who used illegal drugs; and to live
in Canberra (Bammer et al. 1995b*).
The 1994 Canberra survey showed that the government has more to
gain than to lose by running a trial. In response to the question
“If the ACT government decided go ahead with a trial, would that
make you more or less likely to support them?”, 35 per cent (31,38)
reported that they would be more likely to support the government,
50 per cent that it would make no difference and 16 per cent that
they would be less likely to support the government. In addition, in
response to the question: “If the ACT government decided NOT to go
ahead with a trial, would that make you more or less likely to
support them?”, 24 per cent (20,27) reported they would be less
likely to support the government, 66 per cent that it would make no
difference and 11 per cent that they would be more likely to support
the government (Working Paper C in preparation).
Police
The police were only surveyed in 1991. A self-completion mail
questionnaire was sent to 1173 ACT members of the Australian Federal
Police Association, which represents 98 per cent of all Canberra-
based police. Because of time restrictions there was only one
reminder notice, nevertheless there was a 40 per cent response rate.
Police were asked the same question as the general community
(see the 1991 question above) and, of the 446 police who responded,
31 per cent (28,34) thought a trial should go ahead, 63 per cent
that it should not and seven per cent did not know (Bammer et al.
1995b*; Bammer & Crawford 1991*). The police are the only major
interest group opposed to a trial and their lack of support reflects
a value system, pessimism about the outcomes of a trial and concern
about the potential risks that could be associated with a trial. A
number of police comments reflected a negative view of heroin users,
a feeling that they were being given preferential treatment over
more deserving groups and a feeling that a trial was giving in to
the drug problem rather than solving it (Stevens et al. 1995*). Some
representative police comments are:
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“Épeople who take drugs are either mentally sick or hell bent
on self destruction. They have no self discipline. They have, in
most cases, a total disregard for the law and for the community”.
“There are many tax-paying residents of this country deprived
of medical treatment for any number of reasons—locality, non-
availability of service and money. The ill who have contracted
illness through no fault of their own deserve assistance before one
who is self inflicted.”
“Are we going to make females and children available to
rapists? Are we going to give money to bank robbers? Drugs, rape and
armed hold up are all illegal.”
The police were much less likely than the general community to
agree with statements that a trial would improve the health of
users, reduce the spread of HIV/AIDS in the community, reduce crime
or corruption or to agree that “there will always be some people who
take heroin/opiates so it is important to provide them with it in
the safest way” (Bammer et al. 1995a*; Bammer & Crawford 1991*). On
the other hand, police were more likely than the general community
to agree with statements that a trial would increase the number of
people taking heroin, remove incentives for users to give up or cut
back, set a bad example for young people, would be bad for road
safety and to agree that “since governments are worried about the
consumption of drugs like alcohol and tobacco, it seems illogical to
provide heroin/opiates to users” (Bammer et al. 1995a*; Bammer &
Crawford 1991*).
The concerns of police are important and formed the basis of
the analysis of risks; however, the views of police should not
predominate over the views of other key groups, particularly the
general community.
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Service providers
The providers of treatment and other services to illicit drug
users were also only surveyed in 1991. Self-completion mail
questionnaires were distributed through relevant agencies; more than
90 per cent of appropriate agencies agreed to participate. Ninety-
four service provider questionnaires were returned and it was
calculated that this represented 38 per cent of potential
respondents (although there is no certainty that all those eligible
received questionnaires and some may have completed the user/ex-user
questionnaire; Bammer & Crawford 1991*).
Seventy-one percent (64,79) of service providers thought a
trial should go ahead 19 per cent thought it should not and nine per
cent were undecided (Bammer et al. 1995b*; Bammer & Crawford 1991*).
Only 36 per cent of those with a personal philosophy of abstinence
were in favour of a trial compared with 86 per cent support from
those who did not report an abstinence philosophy. There was no
difference in support for a trial by whether or not service
providers had ever used an illegal drug (two-thirds had used an
illegal drug; Bammer & Crawford 1991*).
Illicit drug users
In the Stage 1 survey illicit drug user respondents were
divided into two groups: those who were current users of heroin or
other illegal opioids (n=62; about half were non-dependent users)
and those who used or had used illicit drugs but who had never used
heroin or other opioids (n=24). Illicit drug users were accessed
through agencies providing treatment and other services and through
four friendship networks. The difficulty with surveying illicit drug
users is that there is generally no way of knowing how
representative respondents are.
Of the respondents who currently used opioids, 93 per cent
thought a trial should go ahead, three per cent that it should not
and three per cent were undecided. Of the respondents who used
illicit drugs but had not used opioids, 63 per cent thought a trial
should go ahead, 25 per cent that it should not and 13 per cent were
undecided. The views of the second group were similar to those in
the general community (Dance et al. 1995*). Eighty-two percent of
current opioid users reported that they would be interested in a
place on a trial (Bammer & Crawford 1991*).
In Stage 2, only dependent heroin users were surveyed.
Respondents were divided into three groups: people currently in
methadone treatment, people who had never been in treatment and
people who had dropped out of treatment. There were two separate
surveys of people in methadone treatment. There was a 65 per cent
response to a short self-completion questionnaire which was given to
225 of the 260 clients on the program. In addition, 65 clients were
interviewed; not all had completed the short questionnaire.
It can be seen that although there was a high level of support
for a trial, a substantial percentage of respondents did not want a
place on a trial or were undecided (Tables 6 and 7; Working Paper C
in preparation).
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Table 6
Methadone
clients
%
Methadone
clients
%
Never in
treatment
%
Treatment
drop-outs
%
trial should
go ahead 82 87 100 100
trial should
not go ahead 8 8 0 0
undecided 10 5 0 0
N 146 63 14 8
type of survey self-
completion
interview interview interview
Table 7
Methadone
clients
%
Methadone
clients
%
Never in
treatment
%
Treatment
drop-outs
%
want a place
on a trial 64 68 50 63
do not want a
place on a
trial
17 14 14 13
undecided 19 19 36 25
N 146 65 14 8
type of survey self-
completion
interview interview interview
Ex-users
As with illicit drug users, the problem with surveying ex-users
is that it is not possible to draw a random or even representative
sample. In the Stage 1 survey, people who had been dependent on
heroin in the past were accessed, along with users (and using the
same questionnaire), through agencies providing treatment and other
services and through four friendship networks. Forty-five ex-users
responded. In Stage 2 a variety of methods was used to recruit
people who had given up in four different ways— with minimal or no
formal treatment, through detoxification, through a methadone
program and through a therapeutic community. There were eighteen
participants.
In the Stage 1 survey, 62 per cent of respondents supported a
trial, 22 per cent were opposed and 16 per cent were undecided;
their views were similar to those of the general community (Dance et
al. 1995*; also Appendix in Bammer & Weekes 1993*). In the Stage 2
survey, 47 per cent of respondents supported a trial, 41 per cent
opposed it and 12 per cent were undecided. There was no relationship
between support for a trial and the way the participants had stopped
dependent use. Those who supported a trial generally felt that it
would provide a new treatment option and that it would have positive
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effects on health and criminal behaviour. Some also argued that it
would be easier to become abstinent from heroin than from methadone.
Those who opposed a trial generally reported that it would work
against helping people find the motivation to deal with underlying
problems and therefore would not return them to a normal life. They
also argued that there would be a range of logistic problems and
risks (Bammer & Weekes 1993* 1994*).
The Aboriginal community
It is important to know if a trial of controlled
diacetylmorphine availability would have a particular impact on
local Aboriginal heroin users and on the Aboriginal community
generally. Nineteen Aboriginal community leaders and 28 service
providers were interviewed. Among the community leaders, 53 per cent
thought a trial was appropriate for Aboriginal heroin users, 42 per
cent did not and five per cent were undecided. Of the service
providers, 53 per cent thought a trial was appropriate, 25 per cent
did not, four per cent thought ‘maybe’ and 18 per cent did not know.
Three of the service providers interviewed were Aboriginal and all
thought that a trial was appropriate. In general, both the
advantages and disadvantages of the trial proposal were seen to
apply equally to Aboriginal and non-Aboriginal users (Humes et al.
1993*).
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2. The legal aspects of a trial
Drug legislation
In Stage 1, there was examination of international treaties which
Australia has ratified and Commonwealth, State and Territory
legislation which would impact on a trial (Norberry 1991*). Civil
and criminal liability issues were examined in Stage 2 (Cica 1994*;
Bronitt 1995*).
The relevant international treaties are:
• the Single Convention on Narcotic Drugs 1961 as amended by the
1972 Protocol; and
• the United Nations Convention Against Illicit Traffic in Narcotic
Drugs and Psychotropic Substances 1988.
A trial expanding maintenance treatment to include
diacetylmorphine, that was conducted for a medical or scientific
purpose would not place Australia in breach of international treaty
obligations (Norberry 1991*). Norberry also argued that while, in
these circumstances, controlled availability of diacetylmorphine to
heroin dependent persons was unlikely to involve a breach, inclusion
in a trial of users who are not dependent could be more problematic.
Relevant Commonwealth legislation includes:
• Customs Act 1901 (Cwlth)
• Customs (Prohibited Imports) Regulations
• Narcotic Drugs Act 1967 (Cwlth)
• Therapeutic Goods Act 1989 (Cwlth)
• Crimes (Traffic in Narcotic Drugs and Psychotropic Substances) Act
1990 (Cwlth).
The Commonwealth controls the importation of narcotic goods and
has extensive powers in relation to therapeutic goods. The
Commonwealth and the states also regulate the manufacture of
narcotic goods. In the case of imported heroin, a trial could only
proceed legally if the requisite Commonwealth licences and
permissions were obtained and if the Commonwealth agreed to notify
estimates for heroin importation to the International Narcotics
Control Board (Norberry 1991*; Bronitt 1995*).
The relevant ACT provisions prohibiting possession, supply,
administration and self-administration of heroin are found in:
• Drugs of Dependence Act 1989 (ACT).
Under current ACT legislation, a trial to provide opioids, such as
heroin, in a controlled manner would not be lawful. For a trial to
be able to proceed, one of three changes would have to be enacted:
• a non-enforcement agreement involving the Commonwealth, ACT, some
State governments (probably) and a range of agencies including the
Australian Federal Police, the Director of Public Prosecutions and
the ACT Board of Health,
• amendments to existing ACT legislation, or
• special legislation.
Of these options, the second or third are most desirable (Norberry
1991*; Bronitt 1995*).
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Unless the strict requirements for manufacture of heroin which
exist in Victoria could be met, legislative change would be needed
if the diacetylmorphine was to be manufactured in Australia
(Norberry 1991*); it is more likely, however, that the
diacetylmorphine would be purchased through legal commercial
channels outside Australia. There may also need to be legislative
change in some states to enable the diacetylmorphine to be
transported into the ACT (Bronitt 1995*).
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Liability for harm to participants
In terms of civil liability, researchers or clinical staff will
be liable in negligence to a trial participant or other person
affected by the conduct of the trial if the following elements are
all present: the researcher owed a duty of care to that person; the
duty was breached; the breach caused that person to suffer damage;
and the damage is compensable at law. Liability in negligence will
only attach where the harm caused is the result of breach of duty to
conduct procedures with reasonable care by researchers or clinical
staff (Cica 1994*).
Civil liability in battery arises out of the touching of
another person without that person’s legally valid consent (Cica
1994*). In addition, failure to obtain effective and valid consent
from trial participants would give rise to criminal liability for
assault and/or related offences, except where treatment is provided
in emergency situations. The “public interest” places limits on
consent where the activity involves the risk of bodily harm. It is
unclear, under the present law, whether the treatment or procedures
during the trial could be justified under the existing “medical
treatment” exception, or some other “public interest” exception
(Bronitt 1995*).
To avoid liability for homicide, researchers and clinical staff
must ensure that both foreseen and reasonably foreseeable risks of
death to participants during a trial are minimised (Bronitt 1995*).
The provision of diacetylmorphine to participants may give rise
to liability under poisoning offences. It is unclear whether, and to
what extent, the consent of participants would operate as a defence
(Bronitt 1995*).
To avoid civil liability in battery, the following requirements
must be satisfied: the trial participant must be competent to
consent; the consent must be based on adequate information; the
consent must be voluntarily given; and the consent must not be
against the public interest (Cica 1994*). There are less stringent
requirements for consent in the criminal law, which requires
participants to comprehend only the physical nature of the treatment
and procedures (Bronitt 1995*). However, for both legal and ethical
reasons, trial participants should be fully informed, both in
writing and orally, about the nature, purpose, significance and
context of the treatment and procedures before and during the trial.
In addition, it would be appropriate for the ACT legislature to
enact a special “consent” defence for assault and related offences
(including poisoning offences), which would clarify that staff who
administer diacetylmorphine during the course of a trial can raise
the consent of the participants as a defence (Bronitt 1995*).
Ancillary liability
Criminal liability for the crimes committed by trial
participants was also examined (Bronitt 1995*). In the ACT the
common law offence of misprision of felony is no longer available:
mere knowledge that a participant has committed an offence, and
failing to report that offence to the relevant authorities, is not
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sufficient to impose criminal liability on researchers or clinical
staff. However, liability as an accessory after the fact could occur
where the knowledge is accompanied by positive acts of assistance,
which enable the perpetrator to escape punishment or to dispose of
the proceeds of the offence.
An important issue is that of clinical staff potentially aiding
and abetting driving offences, notably driving under the influence
or culpable driving, either through (a) the act of supplying the
diacetylmorphine or (b) the failure to take steps to prevent the
participants from driving while under the influence of the drug.
Clinical staff, however, would ordinarily lack the requisite
intention to be guilty of aiding and abetting and may in any event
avoid liability by taking steps to dissociate themselves from the
criminal purpose of the participant (Bronitt 1995*).
To avoid liability for public nuisance, which is both a crime
and a tort, researchers and clinical staff must ensure that dangers
to the general public are kept to a minimum. Such steps would
include, for example, the establishment of procedures for the safe
disposal of used needles and syringes and effective security for
diacetylmorphine kept on the premises. The conduct of groups of
participants may attract police intervention through public order
offences and the powers to deal with individuals who are intoxicated
in public. To avoid this, the congregation of participants in the
immediate vicinity of the treatment centre should be deterred
(Bronitt 1995*).
Confidentiality
The trial would be covered by the Epidemiological Studies
(Confidentiality) Act 1992 (ACT), which imposes a statutory duty to
maintain confidentiality. This legislation prohibits anyone involved
in conducting the proposed trial from directly or indirectly “making
a record of, divulging or communicating to any person” any
information concerning the affairs of another person, where that
information was acquired by virtue of the conduct of the trial (Cica
1994*). There is some uncertainty over the scope of the powers of
law enforcement agencies to search and seize confidential
information gained during the trial and this should be clarified in
this legislation so that information gained during the trial cannot
be subject to search and seizure by law enforcement authorities.
Procedures should be drawn up in cooperation with law enforcement
agencies to resolve disputes over the privileged nature of the
information gained during the trial and whether or not that
information can properly be the subject of a search warrant (Bronitt
1995*).
In conclusion, if there was a willingness to make appropriate
legislative changes, other legal issues would not constitute a
barrier to a trial proceeding. In particular, an appropriately
designed and conducted trial would not be in breach of Australia’s
obligations under international conventions dealing with narcotics.
High professional and ethical standards would be expected from
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researchers and clinical staff as a matter of course and these would
additionally minimise the risk of civil and criminal liability.
3. Risks associated with running the trial
There are a number of potential risks associated with trialing
the inclusion of diacetylmorphine in expanded maintenance treatment.
Identifying these risks, finding ways to minimise them and, in the
end, assessing whether or not the potential benefits of conducting a
trial outweighed the risks, were essential elements of the Stage 2
research.
The surveys, workshops, discussions with interest groups and
the published literature were all useful in identifying potential
risks. The cause of greatest concern was that dependent heroin users
from around Australia would move to Canberra. In addition, there is
a view that a trial might be the harbinger of more permissive
attitudes to illicit drug use, which could have negative effects
including increased drug use. There are also inter-related risks
concerning opportunity costs, long-terms costs and the possibility
that, once diacetylmorphine maintenance is trialed, the decision
will be irrevocable. A fourth set of risks relates to trial
logistics and how the running of the trial might pose problems for
the community, participants or other dependent heroin users. Finally
there is risk that the trial will not achieve the proposed benefits.
In this section related issues about the morality of a trial and
possible manipulation of public opinion by those with vested
interests are also discussed.
Dependent users from around Australia may move to Canberra
This potential problem has three dimensions: the number of
people who might move, the length of time they might stay and the
consequences of their movement. Possible negative consequences for
Canberra are an increase in visibility of the illicit drug ‘scene’;
an increase in crime, an increased demand on drug-related and other
services, and increased health problems. These issues were
investigated by examining factors that influence migration, so-
called push-pull factors, and by analysing situations that provide
analogies to what may happen in Canberra. These included migration
to Brisbane and Canberra when the New South Wales government moved
to abandon methadone programs between 1978 and 1985 and an
investigation of factors causing open drug scenes in ZŸrich,
Switzerland and Nimbin, Australia (Bammer et al. 1994a*).
There is a risk of an influx of users to Canberra if a trial of
controlled availability of diacetylmorphine proceeds, but measures
can and should be taken to minimise the risk. These measures must
aim to discourage non-Canberra residents from even trying to get a
place on the pilots or trial. This can be accomplished by a
combination of trial design, residency criteria and appropriate pre-
trial publicity about these.
Eligibility for participation in the Canberra-based pilot
studies and trial should be restricted to those able to prove
residency since 1993. (1993 was originally chosen to discourage non-
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residents from moving to Canberra during the Stage 2 research. In
addition, it would be difficult for people to fake residency proofs
for such an extended period.) Potential proofs of residency include:
bank, credit union or building society account; driver’s licence;
social security records or employment records or education enrolment
records; electoral roll; electricity, gas or telephone accounts; and
land or water rates notices or rent receipts or leases (Bammer et
al. 1994a*). More than one proof of residency will be required.
In addition to the residency criteria, there should also be
restrictions related to trial design. The first restriction is to
limit the numbers on the pilots and trial. Second, the pilot studies
will be restricted to dependent heroin users who are or have been on
the ACT methadone program. The combination of limited places and
strict eligibility criteria will greatly reduce both the likelihood
and the perception of the likelihood of non-residents obtaining a
place. Thus to be eligible for one of the 40 places on pilot 1 or
the 210 additional places on pilot 2, the following criteria will
have to be met:
a) ACT resident since 1993
AND
b) currently on the ACT methadone program or dependent
heroin user who has dropped out of the ACT methadone
program
The trial itself will also be open to long-term ACT residents
who have never been in treatment. To minimise the risks to the ACT,
it is recommended that the trial should only proceed if at least two
other Australian cities agree to participate.
These eligibility criteria should be widely disseminated.
Agencies, Australia-wide, which provide treatment and other services
to illicit drug users should be thoroughly briefed on the
eligibility criteria by the ACT Health Alcohol and Drug Service
(Recommendation 11).
Negative consequences in terms of increased crime, increased
demand on drug-related and other services, and increased health
problems can all be best avoided by discouraging non-residents from
moving to the ACT. However, the potential consequence of increased
visibility of the illicit drug ‘scene’ is more likely to result from
an atmosphere of permissiveness towards illicit drug use than from
an influx of users, per se. As discussed in the next section, a
trial should be divorced from such permissiveness and there should
be stringent enforcement of laws against the consumption and sale of
illicit drugs whenever this occurs in public places. Visibility can
also be minimised by choosing trial site location(s) with physical
attributes that discourage congregation, including no space in which
to gather and lack of other facilities (Bammer et al. 1994a*).
A trial may lead to more permissive attitudes to illicit drug use
This concern is manifested in two major ways. One worry is that
prescription of diacetylmorphine will be the ‘thin edge of the
wedge’ and will lead to full-scale legalisation of illicit drug use.
Grants
56
Another is that a trial will send a message either that illicit drug
use is acceptable or that it is less risky (because if people get
into difficulty they can obtain medically prescribed
diacetylmorphine). The concern is that the consequences of such a
message may be to increase drug use. There is also a worry that a
perception of a more permissive attitude in Australia will have
international consequences, either pressure on Australia to reverse
its policy or a loss of credibility in international fora on drugs.
While these concerns are legitimate, none is an inevitable
consequence of expanding maintenance treatment to include
diacetylmorphine prescribing. Diacetylmorphine prescription can and
should be divorced from permissiveness towards illicit drug use. Law
enforcement and educational strategies against illicit drug use
should be maintained. Ideally the introduction of diacetylmorphine
maintenance prescribing should be low-key, but intense media
interest makes this impossible. Nevertheless, where possible,
communication with the media should reinforce the disassociation
between diacetylmorphine prescribing and permissive attitudes
towards illicit drug use.
It is also worth pointing out that, for illicit drug use to be
legalised, Australia would have to breach the international
conventions, whereas this is not the case for the expansion of
maintenance treatment to include diacetylmorphine (Norberry 1991*).
In addition, the availability of diacetylmorphine on prescription in
the United Kingdom has not led to legalisation, nor is there
evidence that there have been more permissive attitudes towards
illicit drug use or greater increases in use than in other western
countries (Working Paper A in preparation).
Opportunity costs, long-term costs and “you can’t turn the clock
back”
There are a number of interrelated concerns which are
underpinned by the high costs of prescribing diacetylmorphine. They
are that trialing an expansion of maintenance treatment to include
diacetylmorphine will prevent other initiatives from being tried
(opportunity costs); that the expense of diacetylmorphine
prescribing cannot be sustained in the long-term (long-term costs);
and that once diacetylmorphine maintenance treatment is tried it
will be difficult to return to the current policy where
diacetylmorphine is completely unavailable (“you can’t turn the
clock back”).
To a large extent, these are political concerns rather than
research issues, but some commentary based on research evidence can
be made. The first area to examine is the cost of diacetylmorphine
prescribing.
Because only small quantities are produced by limited numbers
of legal commercial producers, the cost of diacetylmorphine itself
is relatively high. The need for high security during production,
shipment, storage and dispensing further adds to the cost. In the
Australian and Swiss contexts where diacetylmorphine would be/is
administered at a clinic, there are substantial costs associated
with staffing treatment centres for extended opening hours. In the
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United Kingdom, where diacetylmorphine is dispensed at pharmacies,
there are high costs associated with packaging the drug in sterile
ampoules and there are relatively high dispensing fees (Working
Paper A in preparation).
Thus, the addition of the option of diacetylmorphine to
maintenance treatment will be more expensive than methadone
maintenance alone. Estimates based on the budget for pilot 2 suggest
that this option will be in the mid-range of costs of treatment for
drug dependence—more expensive than methadone, but cheaper than
therapeutic communities, which are relatively expensive, although
still cost-effective. The larger numbers of staff needed in a
program where diacetylmorphine is dispensed will also allow more
counselling and social assistance to be provided than in a standard
methadone program.
Ironically, if expanding maintenance treatment by including
diacetylmorphine is successful in attracting people into treatment
and in retaining them, this will also add to the costs.
Finally, quality evaluation is expensive. While this will not
be a major on-going cost, it is part of the opportunity cost of
conducting a trial of maintenance including diacetylmorphine rather
than some other treatment option. The highly political nature of
diacetylmorphine prescribing and the need to monitor a number of
social effects would make evaluation of this option more expensive
than evaluation of many other options.
It was not within the scope of the feasibility study to examine
other new treatment options which might be trialed or to evaluate
whether treatment for drug dependence is more pressing than other
health priorities. However, as has been pointed out earlier, there
have been long-term and persistent calls to trial diacetylmorphine
maintenance prescribing, which have emanated from a number of
government enquiries.
The concern about long-term costs relates to financial
pressures in the health care system as a whole. Although there is no
rigorous recent evaluation of the effectiveness of diacetylmorphine
maintenance treatment, there is pressure on individual prescribers
in the United Kingdom to stop or limit this treatment as a result of
restrictions on health care expenditure (Working Paper A in
preparation). There are similar pressures in Australian, and
particularly the ACT, health care systems. Evidence for the cost-
effectiveness of drug treatment generally has been presented
earlier, but whether or not diacetylmorphine prescribing is
affordable is still largely a political decision. Certainly if a
trial proceeds evaluation of cost-effectiveness is critical.
The final concern is about the irrevocable nature of the
decision to pilot and trial maintenance treatment which includes the
option of diacetylmorphine.
Part of this concern is that even if a trial is found to be
unsuccessful for the majority of participants, there will be
pressure for diacetylmorphine maintenance prescribing to continue
for a minority. From previous experience with the prescription of
diacetylmorphine and other maintenance drugs, there are examples of
where this has happened, as well as examples of programs which have
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been completely shut down (Working Paper A in preparation). The
problem again is predominantly political.
A second component to this concern is that allowing
diacetylmorphine maintenance prescribing to be tried (or even
thinking about it seriously) raises expectations among dependent
heroin users and may make them less likely to be satisfied with
other (cheaper or less politically sensitive) options.
Another way of describing these concerns is that the political
costs of a trial may be substantial. While there is a real research
question to be addressed and some persistent pressure to address it,
expectations that it will be addressed (at least in Australia) are
currently low. Conducting the pilots and trial will change those
expectations and will have long-term political, and probably
financial, implications.
Risks associated with trial logistics
There are a number of potential risks related to the running of
the trial. Some are risks to the community, others are risks to
participants or other illicit drug users. Potential risks to the
community include trial participants driving while affected by trial
drugs; law enforcement becoming more difficult; trial
diacetylmorphine becoming available on the black market; and trial
participants congregating at or near the trial site. Risks to
participants or other illegal drug users include the potential of
violence to participants from non-participants; possible health
problems for babies born to women on the trial; and the risk of a
trial providing inappropriate incentives or of institutionalising or
further marginalising dependent heroin users.
a) Risks from trial participants driving while affected by trial
drugs
Both the Stage 1 and Stage 2 surveys show that a substantial
proportion of those likely to be eligible for a place on the trial
drive motor vehicles and that this would be a significant means of
transport to and from the trial (Bammer and Crawford 1991*; Working
Paper B in preparation). Thus concerns about effects on driving must
be considered seriously.
Participants in the Swiss trials must surrender their drivers’
licences, but this option is unlikely to be workable in Canberra
where the public transport system is much poorer . It is likely that
a proportion of participants would simply drive without a licence,
so the risk would remain.
Methadone maintenance treatment does not impair the ability to
drive a motor vehicle (Chesher et al. 1989) and the best currently
available evidence suggests that trial participants who are
stabilised on diacetylmorphine or diacetylmorphine plus methadone
will also not be impaired (Working Paper D in preparation).
The ability for participants to be stabilised on
diacetylmorphine or diacetylmorphine plus methadone will be tested
in Pilot 1 and unless a significant proportion can be stabilised,
there will be no progression to Pilot 2 (Recommendation 4).
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Driving skills are likely to be affected if participants use
doses of diacetylmorphine which induce drowsiness; experience
significant withdrawal symptoms between dosing sessions; and/or use
other drugs like benzodiazepines and alcohol. As discussed in the
section on evaluation these are all indicators of whether or not
stability has been attained.
It will be a condition of involvement in the pilots and trial
that participants undertake not to drive while their skills are
impaired. Clinics will be equipped with a computer-based battery of
tests which assess human performance skills related to those
required to drive a motor vehicle with safety. Participants who have
concerns about their driving ability will be able to do the tests
and staff can require participants to test their ability before they
leave the clinic. If at any time clinic staff have concerns about
the ability of a participant to drive safely, they must advise that
participant that driving while impaired is not only dangerous but is
also an offence, and that if the participant intends to do so, the
staff are obliged by law to contact the police and can provide no
further assistance to the participant (see Bronitt 1995*).
Ethical concerns are also relevant here and to some of the
other risks discussed in this section (especially the risks to
babies of trial participants). The issue of acts and omissions
concerns the distinction between the blame attaching to harms which
one has somehow caused to happen, as opposed to those which one has
merely let happen. The distinction is, for example, between someone
being involved in a car accident after receiving diacetylmorphine as
part of a trial, as compared to an accident after taking heroin
illegally. Ethicists themselves are deeply divided on the moral
importance of this distinction. Some argue for a deontological
approach, namely that there is an enormous difference between
causing harm and allowing harm to happen, so that harm resulting
from an intentional intervention is a major problem, even if similar
or greater harms might otherwise have happened. Other ethicists
argue for a more utilitarian approach, which judges the harms caused
by the intervention in light of those which would have happened had
there been no intervention. The deontological approach sets a
presumption against any interventions designed to alleviate social
problems. By weighting the harms caused as a consequence of the
intervention more heavily than ones which happened independently,
deontologists make it difficult to trial new approaches. While there
needs to be reasonable certainty that the risks involved in
interventions can be minimised, too heavy a bias in that direction
seems difficult to defend (Ostini & Bammer 1991*; Ostini et al.
1993*).
b) Law enforcement will be made more difficult
A concern voiced particularly by some police was that law
enforcement might be made more difficult, because they would not be
able to differentiate between lawful and unlawful heroin use or
because receiving government-supplied diacetylmorphine would be used
as a ‘defence’ when trial participants were prosecuted for other
offences, such as driving under the influence (Stevens et al.
1995*). Neither of these should eventuate. The only place where
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trial participants would legally be in possession of trial
diacetylmorphine would be at the clinic and they would not be immune
from prosecution for other offences or from offences committed under
the influence of trial diacetylmorphine.
Grants
61
c) Risks of the trial diacetylmorphine becoming available on the
black market
The requirement that trial diacetylmorphine must be injected on
site under strict supervision greatly minimises the risk that
participants will divert this drug.
Strict security and accounting procedures will further minimise
the risk of trial diacetylmorphine becoming available on the black
market.
The experience with the current Swiss trials shows that the
risks can be effectively minimised.
d) The risk of trial participants congregating at or near the
trial site
There are two components to congregation. One is that
participants may gather shortly before opening time, the other is
that they may congregate between sessions. The clinic will be closed
between dosing sessions and overnight. There will be five hours
between sessions and 11 hours overnight in pilot 1 and 3.5 hours
between sessions and 11 hours overnight in pilot 2 and, most likely,
the trial.
If participants are properly stabilised, they should not be in
withdrawal at opening time, so this should remove one potential
reason for congregation. Other reasons for congregation at opening
times (for example, the need to get to work in the morning) should
be examined and, if necessary, opening times adjusted. The provision
of a waiting room at the clinic should help minimise congregation
and clinic location should also be considered from this perspective.
For example, siting a clinic near a shopping centre or park or other
area where there is space or other things to do can encourage
congregation.
It is most likely that clinic staff can prevent congregation by
making it clear to participants that it is unacceptable. In the
worst case scenario, police have a range of powers to prevent a
breach of the peace (Bronitt 1995*).
e) The risk of violence to participants from non-participants
The survey results indicate that illicit drug users, police and
service providers all perceive that trial participants are likely to
be at risk of violence from non-participants (Bammer & Crawford
1991*). The main reason for the risk is that non-participants may
try to intimidate participants out of their diacetylmorphine
prescription. This risk can be minimised by making it clear that
there are no take-away doses of diacetylmorphine, that
administration on site is under strict supervision and that
participants who divert their prescription will be expelled from the
trial.
If only one member of a couple where both members are dependent
on heroin has a place on a trial, this could also provoke violence.
Couples will, therefore, be invited to apply for a place together
and to be randomised as a single unit, so that both receive the same
treatment options.
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f) The risk of problems for babies born to women on the trial
It is generally accepted that the babies of drug dependent
women are at greatest risk when their mothers are using illegal
drugs, mainly because of fluctuating blood levels of drugs, other
drugs that may be used to try to alleviate withdrawal symptoms, and
lack of ante-natal and post-natal care. Stabilising heroin dependent
pregnant women on methadone is an accepted way of minimising these
risks and the limited research evidence available suggests that this
does not have major adverse consequences for their children (eg. see
Finnegan & Kandall 1992). There is no evidence about the effects if
women are stabilised on diacetylmorphine or diacetylmorphine plus
methadone.
One option would be to bar women from the trial. However, there
is a growing ethical, social and political debate surrounding the
question of excluding pregnant or potentially pregnant women from
therapeutic research (see Cica 1994*) In this case it can be argued
that the risks to the children of women excluded from the trial are
likely to be greater than those for children of women on the trial.
While most women are concerned about the potential harms drug use
can have on their babies, many have little knowledge about these
harms and, in any case, find it difficult to modify their drug use
(eg see Appendix in Bammer & Weekes 1993*). Excluding women from the
trial would perpetuate this situation, whereas including them would
give them access to reliable information on which to make informed
decisions, as well as ante-natal and post-natal care.
The civil liability aspects of including pregnant women on the
trial are discussed by Cica (1994*). Liability will only attach
where harm caused is the result of breach of duty to conduct
procedures with reasonable care. Ethically, the issue is a question
of what is best for the woman and baby on medical, pharmacological
and social grounds. The issue of acts and omissions discussed above
is also relevant here (Ostini & Bammer 1991*; Ostini et al. 1993*).
g) The risk of a trial providing inappropriate incentives or of
institutionalising or further marginalising dependent heroin
users
There are a number of components to the risk of inappropriate
incentives: non-dependent users increasing their use in order to
qualify for the trial, ex-users starting to use again and lack of
incentives for users to stop. There is also the question of whether
it is appropriate to allow people who are currently in treatment to
qualify for a place on the trial, in other words to provide an
incentive for people to leave current treatment options. In
addition, there is the risk that bringing dependent users into
treatment will result in institutionalisation or further
marginalisation.
The results of surveys with non-dependent users and ex-users
(Bammer & Crawford 1991*; Bammer & Weekes 1993* 1994* Dance et al.
1995*) indicated that there are risks that some non-dependent users
will increase their use in order to get on a trial and that some ex-
users will be tempted to relapse. However, the surveys indicate that
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these risks are small and that the eligibility restrictions will
reduce them further.
The problem of a lack of incentives to stop using is
potentially more serious. Some dependent users decide to become drug
free when they 'hit rock bottom', in other words when they find
themselves in a crisis which leads to a realisation of how much drug
use has cost them and, often, that they may die if they do not stop
(Bammer & Weekes 1993*; 1994*). A trial may mean that participants
do not 'hit rock bottom'. There is a paucity of evidence about
stopping dependent use, so that it is not possible to gauge the
relative importance of 'hitting rock bottom' compared with other
motivations for becoming abstinent, nor is it possible to gauge
whether or not hitting rock bottom inevitably leads to abstinence. A
counter argument is that there are a number of reasons why dependent
users eventually decide to stop and that it is important to keep
them healthy, socially integrated and outside the criminal
subculture while they are using, so that decision to stop is easier
to make and more likely to be achieved. The pilots and trial may be
able to collect evidence which can shed light on these counter
claims.
There is a similar paucity of evidence for meaningful
reflection on the possible incentive of attracting participants from
other treatments. It is not possible to determine whether it will
happen or how problematic it is. Of most concern, however, is that
current methadone clients will be allowed to apply for a place on
the pilots and trial. However, it is also problematic to refuse them
a place, given the high drop-out rate from methadone treatment. The
pilots and trial will provide an answer to the question of whether
methadone clients are better or worse off when given access to
expanded options for maintenance treatment.
Ethical considerations relevant to this issue are discussed in
Ostini & Bammer (1991*) and Ostini and colleagues (1993*). It is
argued that it is never enough simply to say that incentive effects
exist. Undesirable incentive effects must be balanced against
possible positive outcomes.
There is also a risk that a trial will institutionalise and
further maginalise dependent heroin users. Again, there is little
evidence that can be brought to bear on this question and evidence
must be collected as part of the measurement of the effects on
social integration.
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The trial will not achieve the proposed benefits; a trial is morally
wrong; and the possible manipulation of public opinion by those with
vested interests
Many of those who oppose a trial believe that the proposed
benefits will not be achieved (see eg the police response discussed
earlier) and therefore that a trial risks wasting money and effort.
If there were certainty about the outcomes of a trial, it would not
be necessary or ethical to conduct it. However, that certainty does
not exist and, as discussed in Part 2, has been one reason for the
persistence of debate about diacetylmorphine maintenance treatment.
Thus there is a risk that the trial will not produce the proposed
benefits, but, because of the importance of resolving the debate,
that risk should be taken. A negative result would also be useful.
It would significantly mute the debate and allow more attention to
be focused on other possibilities for treatment.
Opposition to a trial is often associated with a value system
which holds illicit drug users in scant regard or a moral position
which is opposed to maintenance treatment. Ward and colleagues
(1992) have discussed the latter as it applies to methadone
maintenance treatment and that argument is also relevant to
expanding this treatment to include diacetylmorphine. Some critics
find it unacceptable to replace “one drug of dependence with
another” (Ward et al. 1992, p. 6) and argue that dependent users
should become drug-free. As Ward and colleagues discuss, showing
that a moral position is empirically impossible, or at least
extremely difficult to meet, provides a good reason for rejecting or
modifying it. Indeed proponents of methadone maintenance argue on
moral utilitarian grounds that the benefits of the treatment to both
the patients and the community outweigh the costs. A trial will
examine if the same holds if maintenance treatment is expanded to
include diacetylmorphine.
This discussion also raises ethical issues related to
countermobilisation (Ostini & Bammer 1991*; Ostini et al;. 1993*).
There are two main sources of opposition to a trial. The first is
from people who feel such a trial is wrong or have genuine anxiety
about its likely outcomes. This opposition is legitimate and must be
respected. The second is from people who have a vested interest in
heroin remaining completely illegal, for example, because they
benefit financially from the sale of illegal drugs. There is a risk
that people in the second group will use the legitimate concerns of
the first group for their own ends; in other words legitimate
concerns could be illegitimately exploited. Apart from being aware
of the issue and evaluating debate, there is little that can be done
about the manipulation of public opinion by those with vested
interests.
4.  A model for service provision
A model for service provision was proposed during the Stage 1
research and was further developed during Stage 2. The Stage 2
considerations were both philosophical and practical. At the end of
this section there is a discussion of the reasons for changes
between the Stage 1 and Stage 2 models.
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Principles of service provision
A small working group considered principles of service
provision which constitute a health development approach (McDonald
et al. 1994*; the health development principles arise from a broader
program of research by one of the group members, Dr David Legge).
Four health development principles are:
• service delivery is undertaken in a respectful collaboration with
the people whose health is at issue (at both the clinical and
community levels);
• service delivery addresses the immediate needs of sick care and
public health in ways that also contribute to redressing problems
understood in terms of larger structures and longer time horizons;
• service delivery addresses the technical tasks of sick care and
public health in ways that also strengthen our ability to manage
existential challenges;
• service delivery conceives the functions of sick care and public
health as continuous with the broader domains of living a
fulfilling life and contributing to building a better society.
The way these principles would translate in terms of the
provision of a service which expands maintenance prescribing to
include diacetylmorphine are discussed by McDonald and colleagues
(1994*). They include a collaborative approach between staff and
participants to dealing with drug use and the problems arising from
it, and the fostering of personal and social reponsibility.
Practical issues
In terms of practicalities, consideration was given to the
location and design of one or more clinic sites; staffing; security;
eligibility to participate; day-to-day operation; and pilot or trial
termination. These are elaborated in Working Paper E (in
preparation) and there are also further details in the budget
justification in Part 4.
a) Location and design of the clinic
The clinic site where diacetylmorphine maintenance prescribing
is an option should be physically separate from the existing
methadone clinics during the pilots and trial. This is to minimise
friction between trial participants allocated to the ‘choice’ group
and those allocated to the ‘control’ group, as well as those
unsuccessful in obtaining a place on the pilots and trial. The
clinic site for the ‘choice’ group must have provision for an
injection room, where a few participants can administer injectable
diacetylmorphine under close supervision. The current Swiss trials
provide a number of models for clinic arrangments that maximise
efficient flow-through of participants.
Thus there will be a clinic(s) for those receiving methadone
maintenance only, which will be attended by those who do not want or
are not eligible or are otherwise unsuccessful in obtaining a place
on the pilots and trial, as well as trial participants allocated to
the ‘control’ group in pilot 2 and the trial. There will be a
different clinic for the expanded maintenance program which will be
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attended by all participants from pilot 1 and those allocated to the
‘choice’ group in pilot 2 and the trial.
It is likely that one site will be able to accommodate the
participants of the expanded maintenance group in pilots 1 and 2; a
second site may be needed to accommodate the larger number of trial
participants in the ‘choice’ group. Although one clinic site is the
cheapest option, and has been the basis for the budget calculations,
it does have disadvantages. It may make the site more conspicuous,
increase the likelihood for congregation and make it more difficult
for participants who want to disassociate themselves from their past
lives or who simply want to avoid other participants.
Considerations for choosing a clinic site include: security;
inconspicuous location; proximity to public transport; public
acceptability; minimisation of opportunity for congregation by
participants; and participant preference. Two-thirds of those
interviewed for the Stage 2 research reported a preference for a
site in Civic (the central area of Canberra; Working Paper B in
preparation).
b) The diacetylmorphine
Diacetylmorphine hydrochloride can be purchased through legal
commercial channels outside Australia. It is available as a sterile
powder. It is not stable in solution in the long term, so that
solutions must be mixed daily. The appropriate dose will be drawn up
into a syringe in front of the participant at each dosing session.
Diacetylmorphine will only be available in injectable form.
Experience in the Swiss trials has shown that no satisfactory
smokable form is available. The Swiss are investigating inhalant
preparations and slow-release oral tablets and if these are shown to
be successful, they should also be included in the Australian trial.
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c) Staffing
A combination of medical, nursing and counselling staff is
envisaged. There might also be advantages to employing pharmacists
to dispense the diacetylmorphine, but this has not been considered
here. Staffing details are provided in the budget justification in
Part 4. There will be regular medical review of the participants and
counselling and social support will be available.
A case work system is proposed, where each nurse and counsellor
will be the caseworker for a specific group of participants and will
be responsible for initial assessment and review; general support;
continuity of care; the participant’s file; and liaision with
medical and other staff. (To ensure comparability between the
‘choice’ and ‘control’ groups, a case worker system should also be
introduced in the methadone program. In pilot 1, the
diacetylmorphine clinic staff have some ‘excess hours’ which could
be used to establish this system in the methadone clinic.) The
casework load for a full-time staff member will be about 10
participants and will be adjusted on a pro-rata basis for part-
timers.
Current staff of the ACT Health Alcohol and Drug Service will
not be required to work in the clinic where the diacetylmorphine
option is provided unless they wish to do so.
d) Security
There must be strict security to prevent theft of drugs by
staff, participants or outsiders. For obvious reasons, security
measures will not be presented in detail, but will include the usual
requirements for storage and transport of drugs of this type and a
security guard during clinic opening times.
e) Eligibility to participate
As outlined earlier, to be eligible for a place on the pilots
or ACT component of the trial, applicants will have to prove ACT
residency since at least 1993. In addition, to be eligible for a
place on the pilots, applicants must be or have been on the ACT
methadone program. Applicants who have dropped out of the methadone
program must be able to prove dependence on heroin, using current
guidelines for admission to the methadone program.
For the trial itself, dependent heroin users who have never
been in treatment will also be eligible, provided they can meet
residency criteria and can prove dependence on heroin, using current
guidelines for admission to the methadone program.
The following will not be eligible for a place on the pilots or
trial: applicants dependent on prescribed opioids for pain relief;
applicants with current or recurrent major psychiatric illness; and
applicants aged less than 18 years (see Sibthorpe et al. 1993*).
Places on the pilots and trial will not be available as a court
referral option. Positive or negative HIV or hepatitis infection
status will not affect eligibility.
There is a discussion on the ethics of eligibility criteria in
Ostini & Bammer (1991*) and Ostini and colleagues (1993*).
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f) Day-to-day running
Participants in the ‘choice’ group will be able to have
injectable diacetylmorphine, oral methadone or a combination. They
will be able to have a maximum of three injections of
diacetylmorphine per day and the clinic will be open in the early
morning, early afternoon and evening to accommodate this.
Diacetylmorphine will only be able to be administered at the clinic;
there will be no take-away doses. Oral methadone will be available
once daily and will be available in take-away doses, regulated
according to current guidelines. Experience in the Swiss trials
indicates that equivalent doses for these two drugs can be easily
calcuated and the pilot studies will test ease of changing between
different options to determine how flexible the expanded treatment
is. Based on the Swiss experience, there will be a maximum dose of
diacetylmorphine of 800 mg per day. Current guidelines will regulate
the provision of methadone. The aim of dosing will be to achieve
stabilised consumption, within a defined therapeutic range, in order
to allow participants to function normally. There will be low
starting doses and a carefully monitored build-up to the stabilising
dose. Doses which produce drowsiness will be allowed, but
participants who request these doses must come early in the dosing
session, so that they will be in a fit condition to leave the clinic
at the end of the dosing session. The dose requested by participants
will be an important indicator of stability (see next section).
Time-limited maintenance treatment, which attempts to force
participants to achieve a drug-free lifestyle, has not been found to
be successful (Ward et al. 1992). Some participants will require
long-term maintenance treatment, while others will aim to become
drug-free. A full range of psychosocial supports to assist those
participants who choose abstinence should be available.
By and large, these conditions are congruent with those that
interviewees and the reference group thought would be appropriate
and feasible (Working Paper B in preparation). Most interviewees
wanted to inject three times a day or less often and this was
consistent with their current patterns. Seventy percent of those
interviewed wanted an upper limit on the amount of diacetylmorphine
available. A few indicated that access to diacetylmorphine would
help them to stop using methadone and become drug-free. Having to
inject on site and not being able to use when and where they wanted
would be a disadvantage for some, as would the inconvenience of
having to go to the site for every injection. However most also
recognised advantages in not having to worry about theft or being
pressured or tempted to sell the diacetylmorphine. For some having a
site at which to inject was an advantage. In general, longer opening
hours would be needed to accommodate all preferences, but this would
be much more expensive and the Swiss experience indicates it may be
unnecessary.
The Swiss experience shows that participants do not arrive in a
steady stream throughout the dispensing period, but that there are
peak times particularly at the beginning of the session. To cope
with this, a second dispensing area at the clinic is proposed. This
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is analagous to the regulation of customer service in banks, where
the number of tellers available is tied to the number of customers.
The following will be grounds for removing participants from
the pilots or trial and transferring them to another treatment:
diversion of diacetylmorphine (ie smuggling the drug out of the
clinic); bringing illegal drugs or alcohol into the clinic; breach
of confidentiality of other participants; and disregard for their
own health and that of others through unsafe injecting, regularly
coming to the clinic intoxicated with other depressant drugs,
disregard of infection controls, and violence.
Participants who leave the pilots or trial will not be
replaced. Thus it will not be possible for those unsuccessful in
gaining a place on a trial to replace participants.
Payment to participate in the pilots or trial will not be
required. First, it is not usual to ask people to pay to participate
in a trial. Second, enforcing payment is likely to confound
measurement of trial outcomes and would counteract the ability of
the pilots and trial to produce clear answers to the research
questions. However, if diacetylmorphine maintenance prescription is
found to be a successful and viable option, in the long term it
should be paid for like any other treatment option.
An issue which is not yet fully resolved is that of smoking
policy. There will be no smoking in the injecting room, but it will
probably be necessary to allow participants to smoke in the waiting
room. This may have implications for the employment of clinic staff.
Children will not be allowed in the clinic; instead there will
be a children’s program which trial participants can use. The ACT
Intravenous Drug Users League (ACTIV) should be invited to expand
its playgroup into a children’s program. Parents are encouraged to
participate in the playgroup, which has a high level of support and
supervision. Community health nurses regularly attend to ensure that
the health needs of the children are met and to provide information
and education to the parents.
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g) Pilot or trial termination
As part of the informed consent process, participants must
understand that continued availability of diacetylmorphine
maintenance prescription cannot be guaranteed and must be made aware
of the conditions under which the pilots or trial might be
terminated. If either of the pilots was shown not to be successful
under the conditions specified in Part 1 (Recommendations 4 and 6),
diacetylmorphine maintenance prescribing would terminate. This would
occur under the recommendation of a committee established to oversee
the running of the pilot studies and the ACT component of the trial
(Recommendation 8). This committee would also have the power to
recommend that the diacetylmorphine maintenance program should be
stopped at any time.
At the end of the first year of the trial, if the results show
that there is no additional advantage to prescribing injectable
diacetylmorphine over the prescription of oral methadone alone, or
that expanding maintenance treatment by prescription of injectable
diacetylmorphine has value for only a subgroup of dependent heroin
users, the second year should be used to limit or wind down the
prescribing of injectable diacetylmorphine and to gradually return
those in the ‘choice’ group to other treatment options.
To avoid undue politically-motivated interference, the
committee should agree at the outset on reasons for terminating or
modifying the pilots or trial (Ostini & Bammer 1991*; Ostini et al.
1993*).
How and why the Stage 2 model is different from that
proposed in Stage 1
There are two main differences between the model proposed at
the end of the Stage 1 research in 1991 and the Stage 2 model
proposed here. The Stage 2 model has restricted the choices
available to three (injectable diacetylmorphine only, injectable
diacetylmorphine plus oral methadone and oral methadone only)
compared with any combination of diacetylmorphine and methadone in
injectable, smokable or oral forms in the Stage 1 model. The other
is that the Stage 2 model proposes a restricted numbers of places
for the trial, whereas the Stage 1 model proposed unlimited numbers.
There are also some minor changes which bring the service more in
line with current methadone treatment.
Practically, the restriction in options eliminates two likely
choices—smokable diacetylmorphine and injectable methadone.
As outlined earlier, the provision of smokable diacetylmorphine
was not successful in the Swiss trials, although it has been
reported to have been used successfully in the United Kingdom
(Working Paper A in preparation; Bammer et al. 1991*). It is
anticipated that investigation of routes of administration for
diacetylmorphine other than through injection will continue, and if
successful routes are found, they may be introduced as one of the
options for the pilots and trial. (The development of other routes
is important, because injection, particularly intravenous injection,
is the most hazardous to health.)
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While injectable methadone may be preferred by some
participants over oral methadone, only one of the interviewees in
the Stage 2 research reported they would prefer it over injectable
diacetylmorphine (Working Paper B in preparation) and it has not
been found to be a popular choice in the Swiss trials. The real
debate, as has been discussed earlier, is about the addition of the
option of diacetylmorphine to maintenance treatment, hence the Stage
2 model has focussed on this.
There are two reasons for the restriction in numbers of places
on a trial. One is that both the reality and perception that there
are limited places will reduce the likelihood that dependent users
from elsewhere in Australia will move to the ACT. The second is that
it allows a more realistic budget to be developed.
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5.  Trial evaluation
There was extensive discussion in Stage 1 about the ethics of
conducting a trial, compared with simply introducing a new policy
option (Ostini & Bammer 1991*; Ostni et al. 1993*). The real
uncertainties which exist argue for a trial and this proposal will
substantially contribute to resolving those uncertainties.
The ultimate aim of the trial is to determine the effectiveness
and cost-effectiveness of expanding standard oral methadone
maintenance treatment to include the options of maintenance with
injectable diacetylmorphine or the combination of injectable
diacetylmorphine and oral methadone. Both individual and social
effects will be assessed.
Preliminary questions which will be tackled in the pilot
studies are:
• can a substantial proportion of participants be stabilised on
injectable diacetylmorphine or the combination of injectable
diacetylmorphine plus oral methadone?
and
• can injectable diacetylmorphine maintenance treatment be
successfully integrated with oral methadone maintenance treatment
to provide a flexible range of options?
There are three components to measuring effectiveness and cost-
effectiveness:
• the ability of these new options to attract and retain people in
treatment
• the ability of these new options to improve treatment outcomes,
measured at both individual and social levels
• measurement or estimation of dollar costs associated with the
positive and negative effects of introducing these new options.
Some components of the evaluation are straightforward and use
well-established methodologies, others will require extensive
developmental work. A distinction is also made between the minimum
amount of evaluation which must be conducted and which must be
budgeted for in the costs of the pilots and trial and highly
desirable elements of evaluation which can be funded separately. A
full discussion of the research protocol is presented in Working
Paper F (in preparation).
Can a substantial proportion of participants be
stabilised on injectable diacetylmorphine or the
combination of diacetylmorphine plus oral methadone?
This preliminary question will be tested in pilots 1 and 2.
Clearly if a substantial proportion of participants who prefer these
options cannot be stabilised, there is no point in proceeding
further. The key measures of stabilisation are use of illicit
heroin; concurrent use of benzodiazepines and/or alcohol with the
trial drugs; withdrawal symptoms; and the participants’ requested
doses. Participants would be deemed to be stabilised if:
• they are no longer using illicit heroin;
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• they are not presenting at the clinic under the influence of
benzodiazepines and/or alcohol;
• they are exhibiting and reporting no or only mild withdrawal signs
and symptoms when they present at the clinic; and
• once the initial adjustment of doses has been made, there is no or
only minimal increase in doses and, secondly, participants are not
requesting doses which would make them drowsy when they leave the
clinic. (As discussed above, participants can be given doses which
induce drowsiness, provided the doses and timing of administration
are such that the drowsiness will wear off before the participants
leave the clinic.)
The minimum level of assessment budgeted for involves analysis
of self-report measures and of staff and independent researcher
assessments; urinalysis; minimal pharmacokinetic analysis and some
psychopharmacological test battery analysis (Working Paper F in
preparation). It would be desirable to have more extensive
pharmacokinetic and psychopharmacological analysis to examine the
relationship between blood levels of the drug and physiological and
behavioural effects, including a full analysis of effects on
driving.
Can injectable diacetylmorphine maintenance treatment be
successfully integrated with oral methadone maintenance
treatment to provide a flexible range of options?
It is fundamental to the proposal that maintenance treatment
provides three options—injectable diacetylmorphine alone, injectable
diacetylmorphine plus oral methadone, and oral methadone alone—and
that participants have flexibility in moving between these options.
For example, only oral methadone will be available to be taken away
from the clinic (under current guidelines), so that if participants
are unable to attend the clinic they must be able to move easily
from the other options to oral methadone alone (and back again).
The flexibility of movement between options has both
pharmacological and service provision components. Experience from
the Swiss trials suggests that there is no problem calculating
equivalent doses for diacetylmorphine and methadone, but there is as
yet no evidence about the ease of movement between options.
From the point of view of service provision, integration would
be achieved if participants and staff made appropriate use of the
range of options; were satisfied with them; and if the availability
of the range of options did not affect the ability to provide oral
methadone maintenance treatment to those who want only that option.
The minimal level of assessment budgeted for includes analysis
of prescribing records; surveys of trial participants and staff; and
some pharmacokinetic and psychopharmacological analysis. Again it
would be highly desirable to undertake more extensive
pharmacokinetic and psychopharmacological analysis.
Does expanding maintenance treatment to include
diacetylmorphine attract dependent heroin users into
treatment and does it improve retention?
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There are two target groups for the first part of this
question—dependent heroin users who have dropped out of treatment
and dependent heroin users who have never been in treatment. The
second part of the question concerning retention is also relevant to
participants from methadone treatment who prefer an expanded range
of options. Answering these questions will require examining pre-
trial data about movement into and out of treatment. This can be
strongly influenced by, for example, changes in policy which can
affect the number of places available, criteria for expulsion and so
on. Providing a valid and reliable answer is therefore statistically
complicated and will require developmental work.
The budget allows for the employment of a statistician to
undertake this developmental work in pilot 2. A statistician will
also need to be employed to analyse the data from the trial.
Does expanding maintenance treatment to include
diacetylmorphine improve treatment outcomes, measured at
both individual and social levels
The value of attracting and retaining people in treatment
hinges on the success of the treatment, therefore this question is
central to the evaluation.
a) Outcomes for trial participants
A randomised controlled trial is the most effective method of
assessment at the individual level. Participants who volunteer for
and are eligible for a place on the trial will be randomly allocated
to either the ‘choice’ group, which provides the expanded treatment
option, or to the ‘control’ group, which provides only oral
methadone. The outcomes to be assessed are health, including
HIV/AIDS and hepatitis risk behaviours and licit drug use; criminal
behaviour, including illicit drug use; and social functioning. There
are standard instruments for measuring these outcomes, such as the
Opiate Treatment Index, but instruments which ask a broader range of
questions will also be developed (Working Paper F in preparation).
However randomised controlled trials do not work if
participants in the control group feel particularly disadvantaged.
In recent years there has been growing resistance by participants
and, often, service providers to randomised controlled trials.
While there is a strong case for running a randomised
controlled trial to assess the effects of addition of
diacetylmorphine to maintenance treatment, it may be difficult to
convince participants, in particular, that this is the case. Pilot 2
will assess whether or not a randomised controlled trial is likely
to succeed. One possible way to encourage those allocated to the
‘control’ group to participate is to guarantee them a place in the
‘choice’ group for the second year of the trial. Other incentives
may also be needed for people in this group and it can be argued
that this is a matter of justice, as it is unfair to ask people to
participate unless there is some benefit to them (Ostini and Bammer
1991*; Ostini et al. 1993*). With current uncertainty about future
changes to the methadone program, it is not possible at this stage
to determine what appropriate incentives may be. Care must also be
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taken that people who want only oral methadone are not significantly
disadvantaged.
If a standard randomised controlled trial is not workable,
Jarrett and Solomon (1994*) have proposed a modification which could
be investigated further.
Attewell and Wilson (1994*) have investigated statistical
issues involved with conducting a standard randomised controlled
trial, particularly power and sample size considerations. They
constructed a table with a comprehensive range of values for
determining whether the study population likely to be available
would be adequate for the levels of effect of interest. If the
sample size were to be 100 in each of the ‘choice’ and ‘control’
groups, then 80 per cent of the time one would detect improvements
as small as about eight per cent for outcome measures having
frequencies around ten per cent (or 90%) in the ‘control’ group and
this increases (decreases) to about 18 per centfor outcome measures
having frequencies around 50 per cent in the ‘control’ group. The
sample sizes proposed will be adequate to measure the effects of
interest, provided the drop-out rate is not too large. Pilot 2 is
therefore crucial to determining whether a randomised controlled
trial is workable.
There are both scientific and political advantages to
conducting the randomised controlled trial in more than one city.
Scientifically, the results will be more able to be generalised. The
illicit drug ‘scene’ varies from city to city, as does the provision
of maintenance treatment and a multi-centre trial would encompass
these variations. However, the delivery of the trial service and
evaluation of results must be strictly comparable between cities.
The investigation would only move to a randomised controlled
trial if the pilots indicated that at least some beneficial outcomes
were likely. Both pilot studies would use participants as their own
controls and would measure effects before and after expanded
maintenance treatment became available. The piloting of the
randomised controlled trial in pilot 2, could also allow an
indication to be gained of whether beneficial outcomes are likely in
the main trial.
Information about outcomes should be obtained both from
interviews with participants and from independent sources, including
police records; medical examinations; random urine tests; and
interviews with relatives.
b) Outcomes for society
Whereas outcome measures for effects on individuals are
reasonably well developed, outcome measures for social effects are
not. These will monitor both the potential benefits of a trial and
the potential risks.
Pilot 1 will investigate the development of a package of
indicators to monitor a number of social effects. Those of interest
include effects on: crime levels and patterns and public perceptions
of crime; illicit drug markets, including leakage of trial drugs
onto the illicit market; drug use patterns, especially among young
people; heroin users moving to the ACT; offensive public behaviour
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by illicit drug users, including the discarding of injecting
equipment in public places; effects on public health and safety,
including numbers of overdoses and drug-related motor vehicle
crashes; and effects on other treatment services, law enforcement
and the ambulance service.
The Stage 2 feasibility research pointed to a number of
potentially useful ways of developing indicators, including the
reintroduction of a modified version of the ACT Drug Indicators
Project (Bammer et al. 1994a*; Bammer & Sengoz 1994); improving the
availability and quality of drug-related crime data (Working Paper F
in preparation); regular monitoring of ambulance service data; and
monitoring the illicit drug market through periodic interviews with
illicit drug users (Bammer & Sengoz 1994*).
Measurement or estimation of dollar costs associated with the
positive and negative effects of introducing these new options.
There should be evaluation of cost-effectiveness as well as
effectiveness. This is relatively new in the drug treatment field
and relies on good measures of effectiveness as well as reliable
indicators of costs for people not in treatment or before they
entered treatment. A health economist should be employed for this
evaluation.
Informed consent and other ethical issues
The exploration of the criminal and civil liability issues
associated with a trial, as well as the ethical issues, have
highlighted the importance of informed consent (Bronitt 1995*; Cica
1994*; Ostini & Bammer 1991*; Ostini et al. 1993*).
It is also crucial that researchers evaluating the outcomes of
the trial do not have restrictions placed on their ability to freely
publish the results of their investigations. In addition, any
empirical data collected should be made publicly available after a
reasonable period, with appropriate protection to prevent
identification of individual participants (Ostini & Bammer 1991*;
Ostini et al. 1993*).
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Part 4:  Budget for the pilot studies and budget
justification
Preparatory phase and pilot 1
Clinic staff
Position Cost per
annum
Preparatory
phase &
pilot 1 cost
Senior specialist (one
position)
155,298 110,500
Service manager (one
position)
70,079 79,512
Nursing staff (six
positions)
one level 2–full-time 53,438 35,968
one level 1–full-time 47,598 32,037
two level 1–70% 67,036 45,120
two level 1–50% 47,598 32,037
Administrative staff
one SOGC–full-time 61,714 70,021
one ASO2–50% 16,854 11,993
Cleaning staff (casual) 7,392
Security staff (@ $500
per week)
16,500
Total clinic staff costs 441,080
Other service provision costs
Item Cost for
pilot 1
Site modifications and
furnishing
125,000
Clinic running costs 50,000
Total other service provision costs 175,000
Total service provision costs 616,080
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Research staff
Position Cost per
annum
Preparatory
phase &
pilot 1 cost
Research director (one
position)
88,279 62,814
Criminologist (one
position)
78,914 50,080
Senior research officer
(one position)
67,303 42,711
Total research staff
costs
155,605
Other research costs
Item Cost for
pilot 1
Research overheads, pharmacokinetic
analyses, computing support 50,000
Total other research
costs
50,000
Total research costs 205,605
TOTAL PREPARATORY PHASE AND
PILOT 1 COST $821,685
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Pilot 2
Clinic staff
Position Cost per
annum
Pilot 2 cost
Senior specialist 155,298 134,393
Community Medical Officer 56,299 50,886
level 2–(0.75 positions)
Service manager (one
position)
70,079 60,645
Nursing staff (twelve
positions)
two level 2–full-time 106,876 9,489
three level–1 full-time 142,793 123,571
one level 1–70% 33,518 29,006
one level 1–60% 28,659 24,801
three level 1–50% 71,396 61,785
one level 1–40% 18,939 16,390
one level 1–20% 9,720 8,412
Counselling staff (six
positions)
one ASO6–full-time 58,399 52,783
one ASO5–full-time 49,648 44,874
one ASO5–80% 40,018 36,170
one ASO5–50% 24,824 22,437
one ASO4–50% 22,949 20,742
one ASO4–40% 18,760 16,956
Administrative staff
one SOGC–full-time 61,714 53,406
one ASO2–full-time 33,709 29,171
Cleaning staff (casual) 20,160
Security staff @ $1,000
per week
45,000
Total clinic staff costs 861,077
Other service provision costs
Item Cost for
pilot 2
Clinical running costs 175,000
Children’s program costs 104,806
Total other service provision costs 279,806
Total service provision
costs
1,140,88
3
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Research staff
Position Cost per
annum
Cost of
pilot 2
Research director (one
position)
88,279 76,397
Criminologist (one
position)
78,914 68,291
Senior research officer
(one position)
67,303 58,243
Statistician (one
position for six months)
37,253
Research assistant (one
position)
45,631 39,489
Total research staff
costs
279,673
Other research costs
Item Cost for
pilot 2
Research overheads, pharmacokinetic
analyses,
computing support
85,000
Total other research
costs
85,000
Total research costs 364,673
TOTAL PILOT 2 COST
$1,505,55
6
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Justification of the budget
Only budgets for the pilot studies have been prepared at this stage.
It will be possible to prepare a realistic budget for the trial once
results from the pilot studies are to hand.
There are a number of considerations which affect several
budgetary items, including the clinical structure and its
relationship to the research, the duration of the pilots, the total
number of clients on the methadone program and the expanded
maintenance options experiment, clinic hours, and pilot termination.
There has been no adjustment in the budget for salary rises,
but all salaries are calculated at the top of the range to allow
some flexibility in hiring, coverage for leave and some salary
increases.
The clinical structure and its relationship to the
research
For the purposes of these budgetary calculations, the
maintenance program which includes diacetylmorphine is considered to
be separate from the methadone maintenance program and to be
separately staffed. It is intended however, that there will be
considerable cross-over between the two groups of staff, although
current methadone program staff who do not wish to work on the
diacetylmorphine maintenance prescribing program will not be
required to do so. Policy and administration for the pilots will be
integrated into the existing Alcohol and Drug Service of ACT Health.
The maintenance clinic which includes diacetylmorphine prescription
will be located at a physically separate site from the existing
methadone clinics.
Pilot 2 participants allocated to the ‘control’ group will
attend the methadone program. There should be continuation of
referral of participants to non-government and other services as
appropriate.
The evaluation team must be independent of the service
provision and will therefore have no role in the day-to-day running
of the service. The evaluation team will be responsible for
recruiting pilot participants, for randomly allocating them to the
‘choice’ and ‘control’ groups (where appropriate) and for measuring
the outcomes of the pilots (and trial). Although the evaluation team
is separate, evaluation is an essential component of the pilots and
must be included in the budgets for the pilots.
Duration of the pilots
Preparatory phase 6 months (minimum)
Pilot 1 7.75 months
Pilot 2 10.25 months
Preparatory phase (Pre-Pilot 1)
After a decision is made to proceed with the pilot studies and
resources are committed, there must be legislative change and the
Commonwealth must grant licences and give permissions (see Part 3,
The legal aspects of a trial). A new clinic must be established and
it will take time to find and refurbish a suitable site. Staff must
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be hired and trained and agreed policy and procedures developed. It
is estimated that this preparatory phase will take six months or
more.
Pilot 1
Clinical timetable
Pilot 1 will begin gradually with ten new participants commencing on
the pilot each week.
Weeks 1–4 10 new participants start each week
Weeks 5–26 40 participants in pilot 1
Weeks 27–30 10 participants have completed six months in
pilot 1 each week (all participants will be
maintained in the pilot until a determination of
success is made in Week 33)
Week 33 end of pilot 1
Research timetable
Pre-pilot (four weeks) Recruit participants, collect pre-pilot data
Weeks 1–30 Analyse dosing records, clinical records and
test battery records on weekly basis
Weeks 1–30 Examination of possible measures of social
impact
Weeks 14–17 Three month interviews with participants and
staff (10 participants per week)
Weeks 27–30 Six month interviews with participants and staff
(10 participants per week)
Weeks 31–32 Collation of analyses and preparation of final
report
Week 33 Decision on whether or not to proceed to pilot
2.
Duration of pilot 1 is 33 weeks (7.75 months).
Pilot 2
Clinical timetable
If the decision is that pilot 1 was a success and therefore
that pilot 2 should proceed, transfer of participants from pilots 1
to 2 and commencement of new participants would begin in Week 34.
Twenty participants would begin on pilot 2 each week.
To minimise the gap between the pilots, staff and participants
for pilot 2 will be recruited in advance of the decision about
whether or not pilot 1 is success, but with clear understanding that
their recruitment is provisional until that decision is made.
Weeks 34–37 10 participants transfer from pilot 1 and 10 new
participants start each week
Weeks 38–46 20 new participants start each week (only 10 in
the last week)
Weeks 47–59 250 participants in pilot 2; 125 in each of the
‘choice’ and ‘control’ groups
Weeks 60–72 20 participants have completed six months in
pilot 2 each week (all participants will be
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maintained in the pilot until a determination of
success is made in Week 78)
Week 78 end of pilot 2
Research timetable
Weeks 34–46 Interviews with new participants to collect pre-
pilot data
Weeks 34–72 Analyse dosing records, clinical records and
test battery records on weekly basis
Weeks 34–72 Analysis of attraction and retention data
Weeks 34–72 Collection and analysis of social impact data
Weeks 47–59 Three month interviews with participants and
staff (20 participants per week)
Weeks 60–72 Six month interviews with participants and staff
(20 participants per week)
Week 73–77 Collation of analyses and preparation of final
report
Week 78 Decision on whether or not to proceed to trial.
Duration of pilot 2 is 45 weeks (10.25 months)
Duration of pilots 1 and 2 is 78 weeks (1.5 years)
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Total number of clients on the methadone program and the
expanded maintenance program which includes
diacetylmorphine prescribing
These budgetary calculations assume that there will no major
changes to the existing ACT methadone program. It is, however,
likely that there will be an increase in private methadone
prescribers and in pharmacy distribution of methadone, although the
speed of introduction of these changes and their magnitude cannot be
estimated at this stage. A consequent ‘freeing up’ of current
methadone program staff could be used to cut pilot staffing costs,
but this is not factored in here. As outlined above, for these
budgetary calculations, the expanded maintenance program which
provides diacetylmorphine is considered to be separate from the
methadone maintenance program and to be separately staffed
Assuming the methadone program has reached a ‘steady-state’ at
350 participants, the likely number of participants in each of the
methadone and expanded maintenance programs are as follows:
In pilot 1, 20 participants will be recruited from the
methadone program and 20 from outside the program, leaving 330
people on the methadone program.
In pilot 2, an additional 130 people will be recruited from the
methadone program, the 20 recruited from the methadone program for
pilot 1 will be transferred to pilot 2, leaving 200 people on the
methadone program. These 150 participants plus the 100 participants
recruited from outside the methadone program (20 in pilot 1 and 80
in pilot 2) will be randomly assigned to ‘choice’ and ‘control’
groups on a 1:1 basis. Thus the 125 people allocated to the
‘control’ group will be returned to the methadone program, so that
there will be 325 people on the methadone program.
The number of participants in the expanded maintenance program
which includes diacetylmorphine will be 40 in pilot 1 and 125 in
pilot 2.
No adjustment has been made to allow for people leaving (either
voluntarily or being expelled from) the expanded maintenance program
which includes diacetylmorphine. Experience with the Swiss trials
has shown a high retention rate7 (Swiss Federal Office of Public
Health, 1995).
Clinic hours
To accommodate those participants who choose to inject
diacetylmorphine three times per day (the maximum permitted), there
will need to be three dispensing times. For pilot 1 the dispensing
times will be 0700 to 0800, 1300 to 1400, 1900-2000. For pilot 2 the
dispensing times will be 0700 to 0900, 1230 to 1430, 1800-2000.
These dispensing times are based on those used in the Swiss
trials, where they have been found to work well. Some participants
                        
7  It is difficult to calculate a precise retention rate because the trials
in different Swiss cities began at different times. In January 1995,
when some trials had been running for 12 months and others for six or
so, the overall retention rate was 81 per cent.
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who request diacetylmorphine only may experience withdrawal symptoms
overnight and they will be offered a low dose of methadone to
alleviate these symptoms.
For pilot 1, in addition to the dispensing times, the clinic
will be staffed for three hours per day, seven days per week. These
additional three hours per day will be used for client case work;
administration; setting up and cleaning up; hand-over between
shifts; and regular staff meetings.
With the additional participant numbers in pilot 2, the clinic
will be staffed from 0630 to 2030.
For both pilots 1 and 2 there will be two rostered shifts.
During pilot 1, excess hours have been budgeted for to give staff,
in conjunction with participants, the necessary flexibility to
develop the best possible clinic operation for Australian
conditions. The excess hours can also be used to assist in the
development of a case work system in the methadone program.
Further details on the day-to-day operation of the clinic are
presented in Working Paper E (in preparation).
Pilot termination
If a decision to terminate is made during the operation of the
pilots, this is unlikely to result in financial problems because
money will already have been committed for the expected original
duration of the pilot.
If the decision at the end of pilot 1 or pilot 2 is that the
pilot was not a success and therefore that there should not be a
progression to a further stage, this will have financial
implications. Staff contracts should be written with this in mind.
Additional funding should be made available for one month at
the end of pilot 1 and for two months at the end of pilot 2 to allow
participants to be transferred to other treatment programs and staff
to find new employment.
This could cost around $50,000 for pilot 1 and $200,000 for
pilot 2.
Clinic staff costs
Senior specialist
Because the pilots are innovative, high profile and highly
political, the head of the clinical service should be a senior
specialist with an established reputation in the illicit drug
treatment field. This person will have a half clinical load and, in
addition will be responsible for the clinical service budget; the
smooth running of the clinical service; liaison with the
researchers; and dealing with visitors to the program and the media.
The senior specialist will be the only medical practitioner
employed in pilot 1. The period of employment should begin one month
before the commencement of the pilot. Hence the period of employment
will be 37 weeks in pilot 1 and 45 weeks in pilot 2.
The annual salary for a senior specialist is $95,470.
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Allowances are $2,737 for administrator in charge; 16 per cent
($15,275) in lieu of private practice; $16,612 special allowance (in
lieu of on-call payments); and $1,336 office allowance.
On costs, calculated at 25 per cent of the annual salary, are
$23, 868.
Other medically qualified staff–Community Medical Officers
Additional medically qualified staff will be needed in pilot 2.
A ratio of one doctor to 100 participants has been allowed. Given
that the senior specialist has a half clinical load (50
participants), a 0.75 position will be needed for pilot 2.
The role of the medically qualified staff will include
participant assessment, establishment of a stabilising dose, dose
adjustments (if necessary), and advising on and monitoring
transitions between the various available pharmaceutical options
(diacetylmorphine alone, diacetylmorphine plus methadone and
methadone alone). Staff should have training in the alcohol and
other drug field and experience in, at least, methadone maintenance
treatment of illicit drug users.
These staff have been budgeted at Community Medical Officer
(CMO) level 2 at an annual salary of $60,052. Allowance has been
made for the doctor(s) in this position to begin work two weeks
before pilot 2. On-costs are calculated at 25 per cent.
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Service manager
The service manager will have responsibility for the
preparatory phase (pre-pilot 1) and will, under direction of the
senior specialist, be responsible for the smooth running of the
clinical service for the pilots.
In the preparatory phase, the duties of the service manager
will include finding a suitable location for the new clinic;
organising refurbishment; hiring and training non-medical staff; and
establishing policy and procedures for the service delivery (in
consultation with the senior specialist). During the pilots the
service manager will be responsible for liaising with the
researchers in the recruitment of participants; the process of
obtaining informed consent from the participants for the clinical
aspects of the pilots; implementing and ensuring the smooth
functioning of a case management system; and liaising with adjunct
services and other treatment services.
The service manager should have training in the alcohol and
other drug field, experience in providing services to illicit drug
users and management and training skills. The service manager should
also have appropriate skills to have a half load in the service
provision (this would cover annual leave for the other staff).
This position has been budgeted at Senior Officer Grade B level
with an annual salary of $56,063, with on-costs at 25 per cent. This
person will be employed for the six months preceding pilot 1, as
well as for pilot 2.
Nursing staff
Nursing staff will have responsibility for dispensing the
prescribed drugs and will, along with counselling staff, be part of
the casework system. Each nurse will be the caseworker for a
specific group of participants and will be responsible for initial
assessment and review; general support; continuity of care; the
participant’s file; and liaison with medical and other staff.
Nurses will work in two shifts (0630 to 1430 and 1230 to 2030)
and, as well as dispensing and case work duties, will have
administrative duties and be responsible for setting up and cleaning
up at each dispensing session.
Six nurses should be employed to work on pilot 1; two full-
time, two at 70 per cent of full-time and two at 50 per cent of
full-time (see Working Paper E in preparation for examples of
rosters). One (full-time) nurse should be employed at level 2, the
others at level 1. The salary for level 2 is $38,750 and for level 1
34,878; on-costs are calculated at 25 per cent. Penalty rates are
calculated at $5,000 per annum for the level 2 nurse; $4,000 per
annum for the full-time level 1 nurse; $3,000 for the 70 per cent
nurses and $2,000 for the half-time nurses. The nurses should be
employed two weeks before the commencement of pilot 1.
No counselling staff will be employed in pilot 1. The casework
load per full-time equivalent staff member will be 9.
Twelve nurses should be employed to work on pilot 2; five full-
time, one at 70 per cent; one at 60 per cent; three at 50 per cent;
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one at 40 per cent and one at 20 per cent. On-costs and penalty
rates are calculated in the same way. Some new nurses will be
employed before the commencement of pilot 2, others will be phased
in as the number of participants increases (for the budget all
calculations are from the beginning of pilot 2). Four nurses must be
available for dispensing at peak demand times. An example of a
roster for pilot 2 is presented in Working Paper E (in preparation).
There will be a total of 4.2 counselling positions (see below),
bringing the casework load per full-time equivalent staff member to
10.
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Counsellors
As well as providing counselling, social support and being case
workers, the counsellors (Administrative Service Officers) could
play an important role by being responsible for the smooth running
of the waiting room. They could undertake a preliminary check of
participants to ensure that they are not intoxicated with other
drugs and therefore unsuitable to be dosed. Final responsibility for
assessing participants for fitness to be dosed rests with the
dispensing staff, but the counsellors could ease the workload of the
dispensing staff by dealing with obviously intoxicated participants.
The counsellors could also be responsible for assessing the
participants’ fitness to leave. However agreement would need to be
reached with the relevant unions for counselling staff to work in
the extended clinic hours and to undertake these new duties.
Six counsellors should be employed to work on pilot 2; two
full-time, one at 80 per cent; two at 50 per cent; and one at 40 per
cent. The annual salaries for different levels are as follows: ASO6
$42,719; ASO5 $36,518; ASO4 $33,519. On-costs and penalty rates are
calculated as for nurses. The counsellors should be employed two
weeks before the commencement of pilot 2. The casework load per
full-time equivalent staff member will be 10 (see discussion for
nurses above).
Administrative staff
A half-time administrative position will be needed at the
clinic in pilot 1 and a full-time position in pilot 2. The person in
this position should be employed one month before the commencement
of pilot 1. This position has been budgetted at ASO2 with an annual
salary of $26,967.
The Swiss experience is that the introduction of
diacetylmorphine prescribing also significantly increases the
workload of ‘central office’ staff because of outside interest and
enquiries. An additional full-time position has been budgetted for
from the beginning of the preparatory phase. This salary has been
budgetted as Senior Officer Grade C at an annual salary of $48,531,
with a $1,050 senior officer allowance.
On costs are calculated at 25 per cent.
Cleaning staff
$16 per hour has been allowed for two hours per day for pilot 1
and four hours per day for pilot 2.
The Swiss have successfully employed trial participants to
undertake cleaning. This could be tried under the supervision of the
service manager.
Security staff
A uniformed security officer will be on the premises during the
clinic opening times. The cost provided by a security firm for three
sessions of two hours duration per day, seven days per week is
around $1,000 per week.
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Other service provision costs
Site modifications and furnishing
This includes internal alterations; on-off security costs; and
furniture and equipment. Some modifications and furniture and
equipment purchases may be delayed until pilot 2. A more detailed
proposal is presented in Working Paper E (in preparation).
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Clinic running costs
This includes the cost of the diacetylmorphine and methadone,
injecting equipment, urinalysis, on-going security costs and
overheads.
The children’s program
The ACT Intravenous Drug Users League should be invited to
expand its playgroup to accommodate a children’s program which pilot
participants will be able to use. This program relies on a
combination of paid workers, parent participation and input from
community nurses.
The children’s program should be open from 0700 to 2030, seven
days per week. There will always be one paid staff member on duty.
The salary has been calculated at the equivalent of three full-time
staff employed at ASO5 level ($36,518 per annum).
$1,000 per month has been allowed to cover other costs,
including insurance, furnishings, food, activities and toys.
This item has been budgetted for pilot 2.
Research staff costs
Research Director
The research director will be responsible for the overall
conduct of the evaluation and for the collation of the analyses and
preparation of the final reports at the end of pilots 1 and 2.
The research director will collect and analyse data on
stabilisation, integration of treatments and individual outcomes.
Because of the larger number of participants, research assistance
will be needed for pilot 2.
The research director will be appointed at the Level D Senior
Fellow with an annual salary of $70,623. On-costs are calculated at
25 per cent. The research director will need to be appointed one
month before pilot 2, to recruit and collect data on participants.
Criminologist
The criminologist will work with the senior research officer to
develop a package of indicators to measure the social impact of
adding injectable diacetylmorphine to maintenance treatment in pilot
1 and to collect and analyse data in order to monitor social impact
in pilot 2.
The criminologist will be appointed at Academic Level 3 with an
annual salary of $57,184. On-costs are calculated at 38 per cent.
Senior research officer
The senior research officer will work with the criminologist to
develop a package of indicators to measure the social impact of
adding injectable diacetylmorphine to maintenance treatment in pilot
1 and to collect and analyse data in order to monitor social impact
in pilot 2.
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The senior research officer will be appointed at Academic Level
2 with an annual salary of $48,770. On-costs are calculated at 38
per cent.
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Statistician
A statistician will be employed for six months full-time in
pilot 2 to develop methods to analyse data on attraction and
retention rates.
The statistician will be employed at Level C Fellow at an
annual salary of $59,605, with on-costs calculated at 25 per cent.
Research assistants
The research director will require research assistance during
pilot 2 to collect and analyse data on stabilisation, integration of
treatments and individual outcomes.
One full-time research assistant will be employed at ANU
Officer 6 levels with an annual salary of $36,505. On-costs are
calculated at 25 per cent.
Other research costs
An allowance was made for overheads, computing support and
limited pharmacokinetic analysis.
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Grant support
1991 $445,000 over 5 years The Australian National University’s
Strategic Development Fund
A Randomised Controlled Trial of New
Treatment Options for Heroin
Dependent People (to G. Bammer and
R.M. Douglas)
1991 $5,040 Criminology Research Council
An Estimation of the Number of
Heroin Users in the ACT
(to G. Bammer)
1992 $8,028 Youth Organisations Research and
Development Grant for collaboration
with the Youth Affairs Network ACT
on Alcohol and Other Drug Use among
Homeless Youth in the ACT
(to G. Bammer)
1993 $16,548 Australian Institute of Aboriginal
and Torres Strait Islander Studies
Grant for collaboration with
Winnunga Nimmityjah (Aboriginal
Health Clinic) on HIV Risk for
Aboriginal Heroin Users in the ACT
(to G. Bammer, O. Brown, D. McDonald
and
B. Sibthorpe)
1993 $56,146 Research Into Drug Abuse Grant for
Illicit Drug Users’ Unmet Treatment
Needs—What Can We learn from
Treatment Drop-outs?
(to G. Bammer, B. Sibthorpe and D.
McDonald)
1994 $29,343 National Drug Crime Prevention Fund
Grant for Narcotic Treatment and
Road Safety
(to G. Starmer, A.F. Moynham, J.
Perl and
G. Bammer)
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The Advisory Committee
Co-chairmen
Professor Bob Douglas NCEPH
Professor Duncan Chappell AIC, to April 1994
Dr Grant Wardlaw AIC, April-November 1994
Dr Adam Graycar AIC, from November 1994
Members
Dr Tony Adams Commonwealth Department of Human
Services and Health
Dr Robert Ali Drug and Alcohol Services Council,
SA
Mr Michael Brown Commonwealth Attorney-General’s
Department (August 1993 to April
1994; observer)
Dr Andy Butlin Alcohol and Drug Service, ACT
Health (to November 1992)
Chief Magistrate Ron Cahill Magistrates’ Court, ACT
Ms Amanda Corkery Dependency Care Foundation Inc.,
ACT (from April 1994)
Professor Terry Carney Faculty of Law, University of
Sydney, NSW
Assistant Commissioner Peter Dawson Australian Federal Police, ACT
Region
Professor Wayne Hall National Drug and Alcohol Research
Centre, NSW
Associate Professor Margaret
Hamilton
Turning Point, Alcohol and Drug
Centre Inc., Victoria
Superindendent Frank Hansen Drug Enforcement Agency, NSW
Professor David Hawks National Centre for Research into
the Prevention of Drug Abuse, WA
Dr Michael MacAvoy Directorate of the Drug Offensive,
NSW Department of Health and
Chair, National Drug Strategy
Committee (October 1992 to April
1994)
Deputy Commissioner Richard
McCreadie
Tasmanian Police and Chair,
National Drug Strategy Committee
(from June 1994)
Mr Kerry McDermott Commonwealth Law Enforcement Board
(to August 1993 and from February
1995; observer)
Ms Tarquin McPartlan ACT Intravenous Drug Users League
(from April 1994)
Mr Michael Moore (MLA) Legislative Assembly for the ACT
Mr Keith Simpson ACT Attorney General’s Department
(from June 1992)
Mr Maarten van der Kleij Alcohol and Drug Service, ACT
Health (from August 1993)
Ms Marion Watson Assisting Drug Dependents Inc., ACT
Dr Don Weatherburn NSW Bureau of Crime Statistics and
Research, NSW Attorney General’s
Advisory committee
96
Department
Dr Alex Wodak Alcohol and Drug Service, St
Vincent’s Hospital, NSW
The Advisory Committee met on 17 February, 1992; 17 June, 1992; 26
October 1992;
12 August 1993; 6 April 1994; and 20 February 1995.
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The Stage 2 Research Team
Dr Gabriele Bammer Fellow, NCEPH; Feasibility Research
Director
Mr Iain Anderson Research Assistant, NCEPH (studies
with dependent heroin users in
and out of treatment)
Ms Robyn Attewell Consultant, NCEPH (statistical
issues for a randomised
controlled trial)
Ms Francesca Baas Becking Research Assistant, NCEPH
(Aboriginal Community AIDS
Project)
Mr Simon Bronitt Lecturer, Faculty of Law, ANU
(criminal liability)
Dr Jim Butler Senior Fellow, NCEPH (economics of
drug markets)
Dr Andy Butlin Visiting Fellow, NCEPH (ACT and
national surveys of community
attitudes)
Ms Jennifer Chadwick-Masters Research Assistant, NCEPH
(migration of illicit drug users
to the ACT)
Ms Natasha Cica Consultant, AIC (civil liability)
Ms Kate Elliot ANU Officer 9, NCEPH (preparation
of grant applications)
Ms Deborah Felton Research Assistant, NCEPH (design
of the service provision
component of the pilots and
trial)
Ms Amanda Goodban ANU Officer 3, NCEPH (general
assistance)
Ms Miriam Hazel Research Assistant, NCEPH (general
assistance)
Ms Glenda Humes Research Assistant, NCEPH
(Aboriginal Community AIDS
Project)
Ms Nova Inkpen Research Officer, AIC (Outcome
measures for a trial)
Professor Richard Jarrett University of Adelaide (trial
design—statistical issues)
Dr Jonathan Kelley Research School of Social Sciences,
ANU (ACT and national surveys of
community attitudes)
Dr Ann Larson Lecturer, University of Queensland
(estimating numbers of heroin
users)
Ms Corinna Lee Research Assistant, NCEPH (studies
with dependent heroin users in
and out of treatment)
Dr David Legge Fellow, NCEPH (philosophy of
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service provision)
Mr David Mascord Research Assistant, University of
Sydney (heroin and driving)
Mr David McDonald Senior Criminologist, AIC (various
projects)
Mr Timothy McGregor Research Assistant, NCEPH
(contribution of childhood sexual
abuse to alcohol, heroin, and
other drug problems workshop)
Ms Michele Moloney Research Assistant, NCEPH
(Aboriginal Community AIDS
Project)
Mr Greg Morris Research Assistant, NCEPH (analysis
of studies with dependent heroin
users in and out of treatment)
Dr Tony Moynham Clinical Forensic Medicine Unit,
New South Wales Police Service
(heroin and driving)
Ms Amanda Neil Research Assistant, NCEPH
(economics of drug markets)
Ms Jennifer Norberry Criminologist, AIC (legal issues)
Mr Remo Ostini Research Assistant, NCEPH (various
projects)
Dr Judith Perl Clinical Forensic Medicine Unit,
New South Wales Police Service
(heroin and driving)
Dr Keith Powell Visiting Fellow, NCEPH (migration
of illicit drug users to the ACT)
Ms Ayse Sengoz Research Assistant, NCEPH (various
projects)
Ms Margaret Shanahan Research Assistant, NCEPH
(contribution of childhood sexual
abuse to alcohol, heroin, and
other drug problems workshop)
Dr Beverly Sibthorpe Fellow, NCEPH (various projects)
Dr Patty Solomon Senior Lecturer, University of
Adelaide (trial design—
statistical issues)
Associate Professor Graham Starmer University of Sydney (heroin and
driving)
Mr Aaron Stowe Research Officer, NCEPH (studies
with dependent heroin users in
and out of treatment)
Ms Heather Strang Executive Research Officer, AIC
(police issues)
Ms Helen-May Timiney Research Assistant, NCEPH
(preparation of grant
applications)
Ms Deborah Tunnicliff Research Assistant, NCEPH (various
projects)
Ms Sue Weekes Research Assistant, NCEPH (ex-users
study)
Professor Sue Wilson Centre for Mathematics and Its
Applications, ANU (statistical
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issues for a randomised
controlled trial)
Collaborations
Winnunga Nimmityjah (Aboriginal Health Clinic) Aboriginal Community
AIDS Project.
Youth Affairs Network of the ACT (YANACT) in a study of alcohol and
other drug use among young people who are homeless or at risk of
being homeless.
Reference Group
Ms Jude Byrne
Ms Phyll Dance
Mr Glenn James
Mr Timothy McGregor
Ms Tarquin McPartlan
Mr Anthony Roben
Ms Margaret Shanahan
Ms Marion Watson
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Workshop participants
The participants in the workshops on Australian drug markets
research: the contribution of childhood sexual abuse to alcohol,
heroin, and other drug problems; and the design and evaluation of a
trial are listed in Working Papers 2, 5, and 8, respectively.
Workshop on Policing Issues, May 30, 1994
Detective Sergeant Don Bailey, ACT Police
Dr Gabriele Bammer, NCEPH
Inspector Tim Fenlon, Queensland Police
Detective Sergeant Tim Fisher, ACT Police
Detective-Superintendent Ted Foster (Co-organiser), ACT Drug Squad
Sergeant Bob Gresham, Australian Federal Police Association
Superintendent Frank Hansen (Chair and co-organiser), Drug
Enforcement Agency, NSW
Intelligence Officer Paddy Mahony, Australian Bureau of Criminal
Intelligence
Deputy Commissioner Richard McCreadie, Tasmanian Police
Superintendent Dennis McDermott, ACT Police
Superintendent Peter McDonald, ACT Police
Commander Rick Ninness, ACT Police
Inspector Steven Vaughn, Victorian Police
Sergeant Rob Wheeler, ACT Legal Services Branch
Dr Grant Wardlaw, AIC
Apologies:  SA Police
Workshop on Cost Considerations for Service Provision for
a 'heroin trial', February 23, 1995
Ms Lia Battinson
Ms Jude Byrne
Ms Phyll Dance
Ms Deborah Felton
Dr Jo Mazengarb
Mr Timothy McGregor
Ms Tarquin McPartlan
Ms Julie Perrin
Ms Margaret Shanahan
Ms Marion Watson
Ms Cheryl Wilson
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Workshop on Medical Issues Involved in Prescribing Heroin
to Dependent Users, February 28, 1995
Dr Robert Ali, Drug and Alcohol Services Council, SA
Dr Gabriele Bammer, NCEPH
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